NZ730861B2 - Antimycotic compound - Google Patents

Abstract

This invention relates to Compound (I), useful in the treatment of mycoses, compositions comprising said compound, and its use in therapy.

Description

COTIC COMPOUND Field of the Invention This invention relates to a compound useful in the treatment of s, compositions containing it and its use in therapy. ound of the Invention The nce of fungal infections has increased substantially over the past two decades and invasive forms are leading causes of morbidity and mortality, especially amongst immunocompromised or immunosuppressed patients. Disseminated candidiasis, pulmonary aspergillosis, and emerging opportunistic fungi are the most common agents producing these serious s. It is a particularfeature of fungi that they are able to generate an extracellular matrix (ECM) that binds them together and allows them to adhere to their in vitro or in vivo substrates. These biofilms serve to protect them against the hostile environments of the host immune system and to resist antimicrobial g (Kaur and Singh, 2013).

Pulmonary aspergillosis can be segmented into those patients suffering with non-invasive disease versus those with an invasive condition. A further vision is used to characterise patients who exhibit an allergic component to aspergillosis (known as ABPA; allergic bronchopulmonary aspergillosis) compared with those that do not. The factors precipitating pulmonary aspergillosis may be acute, such as exposure to high doses of immuno- suppressive medicines or to intubation in an intensive care unit. Alternatively, they may be chronic, such as a previous infection with TB (Denning et al., 2011a). Chronic lung infections with illus can leave patients with extensive and permanent lung damage, requiring lifetime treatment with oral azole drugs r et al., 2011).

A growing body of research suggests that aspergillus infection may play an important role in clinical asthma (Chishimba et al., 2012; Pasqualotto et al., 2009). Furthermore, recently hed work has correlated aspergillus infection with poorer clinical outcomes in patients with COPD (Bafadhel et al., 2013). Similarly cross-sectional studies have shown associations between the presence of Aspergillus spp. and a spp. in the sputum and worsened lung function (Chotirmall et al., 2010; Agbetile et al., 2012).

Invasive aspergillosis (IA) exhibits high mortality rates in immunocompromised ts, for example, those undergoing nic stem cell transplantation or solid organ transplants (such as lung transplants). The first case of IA reported in an compromised patient ed in 1953. This event was concurrent with the uction of osteroids and cytotoxic 40 chemotherapy into treatment regimens (Rankin, 1953). Invasive aspergillosis is a major concern in the treatment of leukaemia and other haematological malignancies given its high incidence and associated mortality. Death rates usually exceed 50% (Lin et al., 2001) and long term rates can reach 90% in allogeneic hematopoietic stem cell transplantation recipients, despite the availiability of oral triazole medicines (Salmeron et al., 2012). In patients undergoing solid organ transplantation (particularly of the lung), the use of high doses of steroids leaves patients vulnerable to infection (Thompson and Patterson, 2008) which is a s problem. The disease has also appeared in less severely immunocompromised patient populations. These include those suffering with underlying COPD or cirrhosis, patients receiving high dose steroids, and individuals fitted with central venous catheters or supported by ical ventilation (Dimopoulos et al., 2012).

Existing ungal medicines are inantly dosed either orally or systemically. These commonly exploited routes of delivery are poor for treating lung ainNays ions, since drug concentrations achieved at the site of infection tend to be lower than those in organs. This is especially so for the liver, which is a site of toxicity: up to 15% of patients d with voriconazole suffer raised minase levels (Levin et al., 2007; Lat and Thompson, 2011).

Exposure of the liver also results in significant drug interactions arising from the the inhibition of hepatic P450 enzymes (Jeong, et al., 2009; Wexler et al., 2004).

Furthermore, the read use of triazoles, both in the clinic and in agriculture has led to a growing and problematic emergence of resistant mycoses in some locations (Denning et al., 2011b; Bowyer and Denning, 2014).

It is clearly evident that an urgent medical need exists for novel anti-fungal medicines that deliver improved efficacy and better systemic tolerability profiles.

Summary of the Invention In a first aspect, the invention provides Compound (|) MN) Me NWO0 — / \ — HNQF F F Compound (I) which is: 4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)tetrahydro furanyl)methoxy)methylphenyl)piperaziny|)-N-(4-fluorophenyl)benzamide, and pharmaceutically acceptable salts thereof (hereinafter sometimes referred to as the “compound of the invention”). ical data disclosed herein below reveals that the compound of the invention, Compound (I), is a potent inhibitor of Aspergi/Ius fumigatus growth in in vitro assays. ln immunosuppressed mice Compound (I) demonstrated potent inhibition of i/Ius fumigatus infections. Other desirable properties of Compound (I) are described herein.

Brief Description of the Figures Figure 1 displays the effects of prophylactic and therapeutic treatment with Compound (I) on CFU in lung of Aspergi/lus fumigatus ed, immuno-compromised, neutropenic mice.

Figure 2 and Figure 3 show the effects of lactic and therapeutic treatment with nd (I) on galactomannan concentrations in BALF and serum respectively, in Aspergi/lus fumigatus infected, immuno-compromised, neutropenic mice.

In s.1-3, the symbol *** indicates significance with P<0.001.

Detailed Description of the Invention Scheme 1: Preparation of Compound (I) by Routes 1-3.

Buchwald Br ' - — Euchillvald (XIVa), Rc — H 0Up In9 Route 1 COUPIINQ Route 2 Route 3 (IX) Ho N\_/N—P W; /—\N@C02Ra (XI) N “'9 0 V(III) o F F (IX) (XIII) l (X) Q 0T5 BUC W8h IdC0U p I'In9 F F (IX) l , Wm, gm<33., Buchwald Coupling gm<3~cNew Deprotect— (V;II Rb—— P Ester 7 (I);Ra= AIkyI _> (V); Rb-— H hydrolysis++0”; Ra_— H NF)N Amide ng H2NO mo 0 F CE“ M2“T<\/> (N 7 (III) \/ F Three alternative, convergent routes which have been developed for the generation of Compound (I) from commercially available starting materials are depicted above (Scheme 1).

These tic ologies differ in the manner in which the advanced benzoate ester intermediates of formula (IV) are prepared.

Route 1 The Buchwald ng of a suitably protected piperazine derivative (XII) with 4-bromo methylphenol (XIVa) under conditions typically employed for such reactions provides the mono N-arylated piperazine (XI). A suitable en protective group for such transformations is as a urethane, using a Boc group (P = COz‘Bu). Those skilled in the art will appreciate that a wide variety of conditions may be used for affecting transformations of this kind. In particular, palladium catalysts and phosphine ligands such as RuPhosG3 and RuPhos are routinely employed in the presence of a base, for example, cesium carbonate or lithium hexamethyldisilazide. Alkylation of the resulting phenol (XI), under basic ions, with the tosylate (IX) generates the ether (VII). The tosylate (IX) is a configurationally stable, non- volatile (solid) reagent that is widely available, in high enantiomeric purity, from commercial sources; though other electrophilic derivatives such as the corresponding mesylate, as well as the halomethyl (e.g. chloromethyl and ethyl) derivatives would be anticipated as suitable atives for this transformation. Removal of the nitrogen protective group reveals the mono-substituted piperazine (V). In the case of a Boc derivative (Rb = COz‘Bu), the amine deprotection step is typically aken by exposure of the carbamate to strong l acid or a strong organic acid, such as TFA, either neat or in the presence of a solvent, such as DCM. A second Buchwald coupling of the amine (V) with an alkyl 4-bromobenzoate (VI), under basic conditions and the agency of a catalyst, gives rise to the N,N'-bisarylated product (IV) in which R8 represents lower alkyl, such as 01.5 alkyl, for example methyl or ethyl, or else tert- butyl.

Route 2 The benzoate ester intermediates (IV), may be obtained in an alternative process in which only a single palladium-mediated coupling is required. Reaction of the bromophenol (XIVa) with a mono N-arylated piperazine derivative [(X), R8 = lower alkyl, such as 01.5 alkyl, for e methyl or ethyl, or else tert—butyl], under rd Buchwald ng conditions, gives rise to a 1,4-bisarylpiperazine (VIII). The O-alkylation of this phenolic product, with the te (IX), as described above, provides the ether products (IV) ly, in two steps, from commercially available starting materials.

Route 3 It will be appreciated from the preparative routes outlined above (Scheme 1) that in some instances it is advantageous to perform the same or similar synthetic transformations in a 40 ent order, so as to improve the overall efficiency of the processes and/or the y of the materials obtained therefrom. For example, the bromophenol (XIVa) may be transformed into the compounds of formula (IV) by conducting the two steps, outlined above, in reverse order. In this manner, ent of the said phenol with the tosylate (IX) provides the ether derivatives of formula (XIII). This aryl bromide substrate may be reacted with an N-aryl zine of a (X), under Buchwald coupling conditions as previously described, to provide the intermediates of formula (IV), Preparation of Compound (I) from ediate (IV) In some cases, for example those in which R8 is methyl or ethyl, generation of the free benzoic acid (II) is conveniently undertaken by treatment of the ester (IV) with a base in the presence of water. Typical conditions include treatment with an alkali metal hydroxide, such as lithium hydroxide, in a mixture of water and a suitable aq miscible solvent. In other instances, as in the case of a tert—butyl ester, it may be advantageous to conduct the hydrolysis step under acidic conditions. Common reagents for such interconversions include strong inorganic acids, for example hydrochloric acid, in the presence of a water miscible, organic t such as IPA.

Treatment of the benzoic acid product (II), with 4-fluoroaniline under standard amide coupling conditions, widely ble in the art, provides the compound of the invention, Compound (I).

For example the reaction may be undertaken by mixing the acid (II) and 4-fluoroaniline with the ng agents HOBt and EDCI in a polar, non protic solvent such as DMF in the presence of a non-nucleophilic organic base, typically DIPEA and the like.

Scheme 2: Preparation of Compound (I) by Route 4. o O my fim m I(I)I WWI“ QF (XII RbNUNWN Br Amide Buchwald CF (xx) Formation (XIX Coupling (XVIII); Rb = P _ b Deprotect (XVII); R = H <— >—\ Buchwald / \ /—\ 0 c Me0\©\ R°\\//N\/N\\//,j<N/—\F, Coupling (XVI); R° = Me— (X'Vb) (XV); R° = H <— F'?‘ NW) /_N 0 Ni 3 0(w Me OT5 RJVO0 a m — o F F (IX) N\ N _ Route 4 The compound of the t invention may also be assembled using yet another variation of the preparative technologies described herein (Scheme 2). In this ative process (Route 4) amide bond formation is undertaken as the first step and tion of the ether linkage constitutes the last synthetic transformation. Acylation of 4-fluoroaniline (III) with 4- bromobenzoyl chloride (XX) provides the anilide fragment (XIX). As already noted such amidic products may be prepared from the corresponding amine and benzoic acid directly using a variety of activating agents, including e coupling reagents, of which a wide choice is available in the art. Subjecting the aryl bromide product to the Buchwald coupling conditions, with a suitable mono-protected piperazine (XII), under the agency of a catalyst in the manner recorded above, gives rise to the intermediates of formula (XVIII). In the case of a Boc protective group [P = COz‘Bu] the d N—aryl piperazine (XVII) is readily obtained by brief exposure to a strong acid, for example, by treatment with TFA, which is then conveniently removed from the reaction medium by evaporation under reduced pressure. The phenolic precursor to compound (I), [(XV); RC = H], was then derived in two steps from a second Buchwald coupling with the anisole (XIVb), to give the methyl ether intermediate [(XVI) RC = Me], followed by an O-dealkylation with boron tribromide. The phenol (XV) was then converted into Compound (I), by re-alkylation with the tosylate reagent (IX) in the manner previously described.

Protective groups and the means for their removal are described in “Protective Groups in Organic sis”, by Theodora W. Greene and Peter G. M. Wuts, published by John Vlfiley & Sons Inc; 4th Rev Ed., 2006, ISBN-10: 7540. A review of methodologies for the preparation of amides is d in: “Amide bond formation and peptide coupling” Montalbetti, N. and Falque, V. edron, 2005, 61, 10852.

Thus the invention also provides a s for preparing Compound (I) or a pharmaceutically acceptable salt thereof which ses reacting a compound of formula (II): N//—\N N Me \\“' \“‘ O N N COZRa F F (H) wherein: R8 represents en; or an activated derivative f (such as an acid halide e.g. an acid chloride or an acid anhydride); or a salt thereof; with a compound of formula (III): H2N0 (III) or a salt thereof.

The invention also provides a process for preparing Compound (I) or a pharmaceutically acceptable salt thereof which comprises reacting a compound of formula (XV): 2015/053731 Hoflflfli\/ \ / \ / HN Q F (XV) or a salt thereof; with a compound of formula (IX): N\N) \\\‘“‘" Z F F (IX) wherein: Z represents a g group such as p-TolylSOzo; or a salt thereof.

Pharmaceutically acceptable salts of compounds of formula (I) include in particular ceutically acceptable acid addition salts of said compounds. The pharmaceutically acceptable acid addition salts of compounds of a (I) are meant to comprise the therapeutically active non-toxic acid addition salts that the compounds of formula (I) are able to form. These pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the free base form with such appropriate acids in a suitable solvent or mixture of solvents. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, , phosphoric acids and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, esulfonic, p- toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic acid and the like.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The definition of the nd of formula (I) is intended to e all tautomers of said compound.

The definition of the compound of formula (I) is intended to include all es of said compound (including solvates of salts of said compound) unless the context specifically indicates othenNise. Examples of solvates include es.

The compound of the disclosure includes embodiments wherein one or more atoms specified are naturally occurring or non-naturally ing isotopes. In one embodiment the isotope is a stable isotope. Thus the compounds of the disclosure include, for example deuterium containing compounds and the like.

The disclosure also extends to all polymorphic forms of the compound herein d.

Novel ediates, as described , of formula (II), (IV), (V), (VII), (VIII), (XIII) and (XV) and salts thereof, form a further aspect of the invention. Salts include pharmaceutically acceptable salts (such as those mentioned above) and non-pharmaceutically acceptable salts.

Salts of acids (e.g. carboxylic acids) e first and second group metal salts including sodium, potassium, magnesium and calcium salts.

In an embodiment there is provided a ceutical composition comprising the compound of the invention optionally in ation with one or more pharmaceutically acceptable diluents or carriers.

Suitably the compound of the invention is administered topically to the lung or nose, particularly, topically to the lung. Thus, in an embodiment there is ed a pharmaceutical composition sing the compound of the invention optionally in ation with one or more topically acceptable diluents or carriers.

Suitable compositions for pulmonary or intranasal administration include s, liquid solutions, liquid suspensions, nasal drops comprising solutions or suspensions or pressurised or non-pressurised aerosols.

The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in ton's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985). The itions may also conveniently be administered in multiple unit dosage form.

Topical administration to the nose or lung may be achieved by use of a non-pressurised formulation such as an aqueous solution or suspension. Such formulations may be administered by means of a nebuliser e.g. one that can be hand-held and portable or for home or hospital use (i.e. non-portable). An example device is a RESPIMAT inhaler. The formulation may se excipients such as water, buffers, tonicity adjusting agents, pH adjusting agents, viscosity modifiers, surfactants and co-solvents (such as ethanol). Suspension liquid and aerosol formulations (whether pressurised or surised) will typically contain the compound of the invention in finely divided form, for example with a D50 of 05-10 pm e.g. around 1-5 pm. Particle size distributions may be represented using D10, D50 and D90 values.

The D50 median value of particle size distributions is defined as the particle size in microns that divides the distribution in half. The measurement derived from laser diffraction is more accurately described as a volume distribution, and consequently the D50 value obtained using this procedure is more meaningfully referred to as a Dv5o value (median for a volume 40 bution). As used herein Dv values refer to particle size distributions measured using laser diffraction. Similarly, D10 and D90 values, used in the context of laser diffraction, are taken to mean Dvm and Dv90 values and refer to the particle size whereby 10% of the distribution lies below the D10 value, and 90% of the distribution lies below the D90 value, respectively. ing to one specific aspect of the invention there is provided a pharmaceutical composition comprising the compound of the invention in particulate form suspended in an aqueous medium. The aqueous medium typically comprises water and one or more excipients selected from buffers, tonicity adjusting agents, pH ing agents, viscosity modifiers and surfactants.

Topical administration to the nose or lung may also be achieved by use of an aerosol formulation. Aerosol ations typically comprise the active ingredient suspended or dissolved in a suitable aerosol propellant, such as a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC). Suitable CFC propellants e trichloromonofluoromethane (propellant 11), dichlorotetrafluoromethane (propellant 114), and dichlorodifluoromethane (propellant 12). Suitable HFC propellants include tetrafluoroethane (HFC-134a) and heptafluoropropane (H FC-227). The propellant typically comprises 40%-99.5% e.g. 40%-90% by weight of the total inhalation composition. The formulation may comprise excipients including co-solvents (e.g. l) and surfactants (e.g. lecithin, sorbitan trioleate and the like). Other possible ents include polyethylene glycol, polyvinylpyrrolidone, glycerine and the like. Aerosol ations are packaged in canisters and a suitable dose is delivered by means of a metering valve (e.g. as supplied by Bespak, Valois or 3M or alternatively by Aptar, Coster or Vari).

Topical administration to the lung may also be achieved by use of a dry-powder formulation.

A dry powder formulation will contain the compound of the disclosure in finely divided form, typically with an MMD of 1-10 pm or a D50 of 05-10 pm e.g. around 1-5 pm. Powders of the compound of the invention in finely divided form may be prepared by a micronization process or r size reduction process. Micronization may be performed using a jet mill such as those ctured by Hosokawa Alpine. The resultant particle size distribution may be measured using laser diffraction (e.g. with a Malvern sizer 20008 instrument). The ation will lly contain a topically acceptable diluent such as lactose, glucose or ol (preferably lactose), usually of comparatively large particle size e.g. an MMD of 50 pm or more, e.g. 100 pm or more or a D50 of 40-150 pm. As used herein, the term “lactose” refers to a lactose-containing component, including d-lactose monohydrate, B-lactose monohydrate, d-lactose anhydrous, B-lactose anhydrous and amorphous lactose. Lactose components may be processed by micronization, sieving, g, compression, agglomeration or spray drying. Commercially ble forms of lactose in various forms are also encompassed, for example Lactohale® (inhalation grade lactose; DFE Pharma), lnhaLac®70 (sieved lactose for dry powder inhaler; Meggle), Pharmatose® (DFE Pharma) and Respitose® (sieved inhalation grade e; DFE Pharma) products. In one embodiment, the lactose ent is selected from the group consisting of d-lactose monohydrate, d-lactose ous and amorphous lactose. Preferably, the e is d-lactose monohydrate.

Dry powder formulations may also contain other excipients such as sodium stearate, calcium stearate or magnesium stearate.

A dry powder formulation is typically red using a dry powder inhaler (DPI) device.

Example dry powder delivery systems include SPINHALER, LER, ALER, DISKUS, SKYEHALER, ACCUHALER and CLICKHALER. Further examples of dry powder delivery systems include ECLIPSE, NEXT, ROTAHALER, HANDIHALER, AEROLISER, CYCLOHALER, BREEZHALER/NEOHALER, MONODOSE, FLOWCAPS, TVVINCAPS, XCAPS , TURBOSPIN, ELPENHALER, MIATHALER, TVVISTHALER, NOVOLIZER, IR, A, ORIEL dry powder inhaler, MICRODOSE, AL, EASYHALER, ULTRAHALER, TAIFUN, PULMOJET, OMNIHALER, GYROHALER, TAPER, CONIX, XCELOVAIR and PROHALER.

The compound of the invention might also be administered topically to another al or al surface (e.g. a mucosal surface or skin) or administered orally. The compound of the ion may be formulated conventionally for such routes of administration.

The compound of the invention is useful in the treatment of mycoses and for the prevention or ent of disease associated with mycoses.

In an aspect of the invention there is provided use of the nd of the invention in the manufacture of a medicament for the treatment of mycoses and for the prevention or treatment of e associated with mycoses.

In another aspect of the invention there is provided a method of treatment of a subject with a mycosis which comprises administering to said subject an effective amount of the compound of the invention.

In another aspect of the invention there is provided a method of prevention or treatment of disease ated with a mycosis in a subject which comprises administering to said subject an effective amount of the compound of the invention. s may, in particular, be caused by Aspergi/Ius spp. such as Aspergi/Ius fumigatus or Aspergi/Ius pu/lu/ans especially Aspergi/Ius fumigatus Mycoses may also be caused by Candida spp. e.g. Candida albicans or Candida glabrata, Rhizopus spp. e.g. Rhizopus oryzae, Cryptococcus spp. e.g. Cryptococcus neoformans, Chaetomium spp. e.g. Chaetomium globosum, Penicil/ium spp. e.g. Penicil/ium chrysogenum and Trichophyton spp. e.g.

Trichophyton rubrum.

A disease associated with a mycosis is, for example, pulmonary aspergillosis.

The compound of the invention may be used in a prophylactic setting by administering the 40 said compound prior to onset of the mycosis.

Subjects e human and animal subjects, especially human subjects.

The compound of the invention is especially useful for the treatment of mycoses such as Aspergi/Ius fumigatus infection and for the prevention or treatment of disease associated with mycoses such as Aspergi/Ius fumigatus infection in at risk subjects. At risk subjects include ure infants, children with congenital defects of the lung or heart, immunocompromised subjects (e.g. those ing from HIV infection), asthmatics, subjects with cystic fibrosis, elderly ts and ts suffering from a chronic health condition affecting the heart or lung (e.g. congestive heart failure or chronic obstructive pulmonary disease).

The compound of the invention is also useful for the ent of azole resistant mycoses such as azole resistant Aspergi/Ius fumigatus infection, particularly in ation with posaconazole.

The compound of the invention may be administered in combination with a second or further active ient. Second or r active ingredients may, for example, be ed from other anti-fungal agents (such as voriconazole or posaconazole), amphotericin B, an echinocandin (such as caspofungin) and an inhibitor of 3-hydroxymethyl-glutaryl-CoA reductase (such as lovastatin, tatin or fluvastatin).

Second or further active ingredients include active ingredients suitable for the treatment or prevention of a mycosis such as Aspergi/Ius fumigatus ion or disease associated with a mycosis such as Aspergi/Ius fumigatus infection or ions co-morbid with a mycosis such as Aspergi/Ius tus infection.

The compound of the invention may be co-formulated with a second orfurther active ingredient or the second or further active ingredient may be formulated to be administered separately by the same or a different route.

For example, the compound of the invention may be administered to patients already being treated systemically with an anti-fungal, such as voriconazole or posaconazole.

For example, the compound of the invention may be co-administered e.g. co-formulated with one or more agents selected from amphotericin B, an echinocandin, such as ungin, and an inhibitor of 3-hydroxymethyl-glutaryl-CoA ase, such as lovastatin, pravastatin or fluvastatin.

The compound of the invention may alternatively (or in addition) be co-administered e.g. co- formulated with one or more agents selected from candicidin, filipin, hamycin, natamycin, nystatin, rimocidin, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, zole, omoconazole, oxiconazole. 40 sertaconazole, sulconazole, tioconazole, albaconazole, efinaconazole, epoxiconazole, fluconazole, onazole, itraconazole, onazole, ravuconazole, terconazole, gin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, micafungin, benzoic acid, ciclopirox, flucytosine (5-fluorocytosine), griseofulvin, tolnaftate and undecylenic acid.

WO 87878 Preferred combination partners include intraconazole, nazole, caspofungin and posaconazole.

According to an aspect of the invention there is provided a kit of parts comprising (a) a pharmaceutical composition comprising the compound of the ion optionally in combination with one or more diluents or carriers; (b) a pharmaceutical composition comprising a second active ingredient optionally in ation with one or more diluents or carriers; (c) optionally one or more further ceutical compositions each comprising a third or further active ingredient optionally in combination with one or more diluents or carriers; and (d) instructions for the administration of the ceutical compositions to a subject in need thereof. The subject in need thereof may suffer from or be susceptible to a mycosis such as Aspergi/Ius fumigatus infection.

The compound of the ion may be stered at a suitable interval, for example once per day, twice per day, three times per day or four times per day.

A suitable dose amount for a human of average weight (50-70 kg) is expected to be around 50 ug to 10 mg/day e.g. 500 ug to 5 mg/day although the precise dose to be administered may be determined by a skilled person.

The compound of the invention is expected to have one or more of the ing favourable attributes: . potent antifungal activity, particularly activity against Aspergi/Ius spp. such as Aspergi/Ius fumigatus or activity against Candida spp. e.g. Candida albicans or Candida glabrata, Rhizopus spp. e.g. Rhizopus oryzae, Cryptococcus spp. e.g.

Cryptococcus neoformans, Chaetomium spp. e.g. Chaetomium globosum, l/ium spp. e.g. Penicil/ium chrysogenum or Trichophyton spp. e.g. Trichophyton rubrum, especially following l administration to the lung or nose; . long duration of action in lungs, preferably consistent with once daily dosing; . low systemic exposure following topical administration to the lung or nose; and . an acceptable safety profile, especially following topical administration to the lung or nose. 2015/053731 EXPERIM ENTAL SECTION Abbreviations used herein are defined below (Table 1). Any abbreviations not d are intended to convey their generally accepted meaning.

Table 1: Abbreviations ABPA allergic bronchopulmonary illosis aq aqueous ATCC American Type Culture Collection BALF bronchoalveolar lavage fluid BEASZB SV40-immortalised human bronchial lial cell line Boc tert—butyloxycarbonyl br broad BSA bovine serum albumin CC5o 50% cell cytotoxicity concentration CFU colony forming unit(s) CLSI Clinical and Laboratory Standards ute COI cut off index conc concentration/concentrated d doublet DCM dichloromethane DFB5o days taken to reach a fungal burden of 50% of control DIPEA N,N-diisopropylethylamine DMAP 4-dimethylaminopyridine DMEM Dulbecco’s Modified Eagle Medium DMF N,N-dimethylformamide DMSO dimethyl sulfoxide DSS dextran sodium sulphate EBM endothelial basal media ECM extracellular matrix EDCI.HC| N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride EGM2 endothelial cell growth media 2 EUCAST European tee on Antimicrobial Susceptibility Testing (ES+) electrospray ionization, positive mode Et ethyl EtsN triethylamine EtOAc ethyl acetate FBS foetal bovine serum GM galactomannan HPAEC human pulmonary artery endothelial cell HOBt.H20 1-hydroxybenzotriazole mono-hydrate 2015/053731 HPLC reverse phase high performance liquid chromatography hr hour(s) IA invasive aspergillosis i.n. intranasal IPA 2-propanol i.t. intra-tracheal LC-MS liquid chromatography—mass spectrometry Li Hep lithium heparin LiHMDS lithium bis(trimethy|si|y|)amide m multiplet (M+H)+ protonated molecular ion MDA malondialdehyde Me methyl MeCN acetonitrile MeOH methanol MHz megahertz MlC5o 50% of minimum inhibitory concentration MIC75 75% of minimum inhibitory concentration Mngo 90% of minimum inhibitory concentration min minute(s) MMD mass median diameter MOI multiplicity of infection MOPS 3-(N-morpholino)propanesulfonic acid m/z: mass-to-charge ratio NCPF National Collection of Pathogenic Fungi NMR nuclear magnetic resonance (spectroscopy) NT not tested OD optical density PBS phosphate buffered saline P protective group 0| quartet RT room ature RP HPLC reverse phase high performance liquid chromatography RPMI l Park Memorial Institute medium RuPhos 2-dicyclohexylphosphino-2’, sopropoxybiphenyl (2-dicyclohexylphosphino-2’, 6’-diisopropoxybiphenyl)[2-(2’-amino-1, RuPhosG3 1’-biphenyl)]palladium thanesulfonate s singlet sat saturated sc sub-cutaneous SDS sodium l sulphate t triplet TFA trifluoroactic acid TH F ydrofuran An Aspergi/Ius fumigatus strain containing a leucine-to-histidine TR34/L98H substitution at codon 98 and a 34-bp tandem repeat General Procedures All starting materials and solvents were obtained either from commercial sources or prepared according to the literature citation. Unless othenNise stated all reactions were stirred. Organic ons were routinely dried over anhydrous magnesium sulfate. ical Methods e Phase HPLC Methods: Waters t CSH C18 XP column, 2.5 pm (4.6 x 30 mm) at 40°C; flow rate 2.5-4.5 mL min' 1 eluted with a Hzo-MeCN gradient containing either 0.1% v/v formic acid (Method a) or 10 mM NH4HCOs in water d b) over 4 min employing UV detection at 254 nm. Gradient information: 0-3.00 min, ramped from 95% H20-5% MeCN to 5% H20-95% MeCN; 3.00-3.01 min, held at 5% H20-95% MeCN, flow rate increased to 4.5 mL min'1; 3.01 3.50 min, held at % H20-95% MeCN; 3.50-3.60 min, returned to 95% H20-5% MeCN, flow rate reduced to 3.50 mL min"; 3.60-3.90 min, held at 95% H20-5% MeCN; 3.90-4.00 min, held at 95% H20- % MeCN, flow rate d to 2.5 mL min'1. 1H NMR Spectroscopy: 1H NMR spectra were acquired on a Bruker Advance ||| spectrometer at 400 MHz using residual erated solvent as reference and unless specified othenNise were run in DMSO- d6.

Synthetic Methods for the Preparation of Compound (I) tert-butyl 4-(4-hydroxymethylphenyl)piperazinecarboxylate.

HO®Br Me HN NBoc —> HO N NBoc RuPhos, RuPhos G3, (Xlla) LiHMDS, DMF (Xla) A flask charged with tert—butylpiperazincarboxy|ate (Xlla) (7.44 g, 40.0 mmol), 4-bromo methylphenol (6.23 g, 33.3 mmol), RuPhos (311 mg, 0.67 mmol) and RuPhos G3 (557 mg, 0.67 mmol) was evacuated and backfilled with nitrogen three times. A solution of LiHMDS (1M in THF, 100 mL, 100 mmol) was added and the reaction mixture was heated at 70°C for 3 hr.

After cooling to RT the mixture was quenched by the addition of 1M hydrochloric acidl (100 mL) and was then neutralised with 1M aq. NaHCOs (100 mL). The aq layer was extracted with EtOAc (3 x 100 mL) and the combined c extracts were dried. The les were removed in vacuo to give a crude product which was purified by flash column chromatography (SiOz, 120 g, 0-100% EtOAc in isohexanes, gradient elution) to afford the title compound, intermediate (Xla), as a light brown solid (7.80 g, 78%); Rt 2.07 min (Method b); m/z 293 (M+H)+ (ES+); 1H NMR 6: 1.41 (9H, s), 2.07 (3H, s), .88 (4H, m), 3.41-3.43 (4H, m), 6.58-6.65 (2H, m), 6.71 (1H, d) and 8.72 (1H, s). ((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)tetrahydrofuran yl)methoxy)—3-methylphenyl)piperazine.

O NUN “‘ OTS \N Me F F (IX) /—\ \~“ 0 N N—Rb (Xla) —> \ / NaOH,DMSO F F — (Vila); Rb = Boc TFA,DCM —> (V);R'°=H To a solution of intermediate (Xla) (7.80 g, 25.1 mmol) in DMSO (60 mL) was added aq sodium hydroxide (3.0 mL, 12.5 M, 37.6 mmol). The e was stirred at RT for 10 min and was then treated portionwise with ((38,5R)—5-((1H—1,2,4-triazolyl)methyl)(2,4-difluoro )tetrahydrofuranyl)methyl4-methylbenzenesulfonate (IX) (ex APIChem, Catalogue Number: AC-8330, 12.4 g, 27.6 mmol). The reaction mixture was stirred at 30°C for 18 hr, cooled to RT and water (200 mL) was added. The resulting mixture was extracted with EtOAc (3 x 200 mL) and the combined organic extracts were washed with brine (2 x 200 mL), and then dried and evaporated in vacuo to afford a brown oil. Analysis of the crude, Boc-protected product (Vlla) by 1H NMR indicated that it contained ~10% of the alkene: (R)—1-((2-(2,4- difluoropheny|)methylenetetrahydrofuranyl)methy|)-1H-1,2,4-triazole, formed as an elimination by-product. The crude urethane (Vlla) was taken up into DCM (150 mL) and treated with TFA (39.0 mL, 502 mmol). After 2 hr at RT the reaction mixture was concentrated in vacuo to remove most of the volatiles and was then d with EtOAc (200 mL) and washed with aq. NaOH (2 M, 200 mL). The aq phase was separated and was extracted with EtOAc (2 x 200 mL). The combined organic extracts were washed with brine (2 x 200 mL) and then dried and evaporated in vacuo to afford a light brown oil. The crude product was purified by flash column chromatography (SiOz, 80 g, 0-10% 0.7 M NHs/MeOH in DCM, gradient elution) to afford the title compound, intermediate (V), as a viscous, light brown oil (9.46 g, 80%); Rt 1.91 min (Method b); m/z 470 (M+H)+ (ES+); 1H NMR 6: 2.07 (3H, s), 2.15 (1H, dd), 2.36-2.42 (1H, m), 2.52-2.56 (1H, m), 2.79-2.81 (4H, m), .90 (4H, m), 3.66 (1H, dd), 3.73-3.77 (2H, m), 4.04 (1H, t), 4.57 (2H, dd), 6.64 (1H, dd), .75 (2H, m), 6.99 (1H, td), 7.25-7.34 (2H, m), 7.76 (1H, s) and 8.34 (1H, s).

Methyl 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)tetra hydrofuranyl)methoxy)methylphenyl)piperazinyl)benzoate. 0com2. o (Vla) \N Br Me (V) N‘ ‘N <_> co Me (lVa) RuPhos,RuPhosG3, mo <3 2 \ / \ / C52C03, DMF F F A flask charged with intermediate (V) (9.00 g, 19.2 mmol), methylbromobenzoate (Vla) (4.95 g, 23.0 mmol), RuPhos (0.18 g, 0.38 mmol, 2 mol%), RuPhosG3 (0.32 g, 0.38 mmol, 2 mol%) and cesium carbonate (9.99 g, 30.7 mmol) was evacuated and refilled with nitrogen three times before DMF (150 mL) was added. The mixture was heated at 80°C for 22 hr and then, whilst still hot, was poured into water (150 mL) to form a brown gum. More water (300 mL) was added and the aq. phase was extracted with DCM (2 x 200 mL). The organic extracts were ed and concentrated in vacuo to give a brown oil which was poured into water (100 mL). The resulting itate was collected by filtration and then re-suspended in THF (100 mL). The mixture was heated at reflux for 1 hr during which time a cream suspension was formed. The mixture was cooled to RT and the resulting itate was collected by filtration, washed with THF (2 x 50 mL) and then dried in vacuo to afford the title compound, intermediate (lVa), as a light yellow solid (9.48 g, 79%); Rt 2.79 min (Method b); m/z 604 (M+H)+ (ES+); 1H NMR 6: 2.09 (3H, s), 2.16 (1H, dd), 2.37-2.43 (1H, m), 2.52-2.58 (1H, m), 3.11-3.14 (4H, m), 3.43-3.46 (4H, m), 3.68 (1H, dd), 3.74-3.79 (5H, s overlapping over m), 4.05 (1H, dd), 4.58 (2H, dd), 6.75 (2H, br s), 6.85 (1H, br d), 7.00 (1H, td), 7.04 (2H, d), 7.25- 7.34 (2H, m), 7.76 (1H, s), 7.81 (2H, d) and 8.34 (1H, s).

Ethyl 4-(4-(4-hydroxymethylphenyl)piperazinyl)benzoate.

H0®Br Me /—\ (XIVa) HN HOQ/—\N \_/N®C02Et —> \_/N®C02Et R_uPhos G3, (Xa) LIHMDS, DMF (Vllla) A flask charged with a solution of ethyl 4-(piperaziny|)benzoate (Xa) (20.0 g, 85.0 mmol) and 4-bromomethylphenol (19.2 g, 102 mmol) in DMF (213 mL) was evacuated and backfilled with nitrogen three times. RuPhos G3 (1.43 g, 1.71 mmol) was added and the flask was evacuated and backfilled with nitrogen. The reaction e was cooled to 0°C and LiHMDS (17.1 g, 102 mmol) was added. The reaction was stirred at RT for 10 min, then cooled in a water bath and LiHMDS (20.0 g, 120 mmol) added in equal portions (7 x 2.85 g) at 5 min intervals. The ing solution was stirred at RT for 30 min and was then cooled to 0°C and d with 2M hydrochloric acid (200 mL) resulting in a pH of 6-7. The mixture was d for 15 min at RT and was then extracted with EtOAc (220 mL). The aq layer was separated 2015/053731 and extracted with EtOAc (4 x 50 mL) and the combined organics were washed with brine (6 x 50 mL), and then dried and evaporated in vacuo to afford a cream solid. A mixture of anes and IPA (1:1, 150 mL) was added and the suspension was stirred at RT for 30 min. The solid was collected by filtration, and the filter cake was washed with a mixture of anes and IPA (1:1, 2 x 10 mL) followed by isohexanes (4 x 10 mL) and dried in vacuo at 40°C for 18 hr to afford the title compound, intermediate (Vllla), as a cream solid (15.3 g, 50%); Rt 2.29 min d b); m/z 341 (M+H)+ (ES+); 1H NMR 6:1.29 (3H, t), 2.09 (3H, s), 3.06-3.09 (4H, m), 3.42-3.44 (4H, m), 4.24 (2H, dd), 6.66 (2H, br s), 6.76 (1H, br s), 7.03 (2H, d), 7.80 (2H, d), 8.72 (1H, s).

Ethyl 4-(4-(4-(((3R,5R)((1H-1,2,4-triazoly|)methyl)(2,4-difluorophenyl)tetrahydro furanyl)methoxy)methylpheny|)piperaziny|)benzoate.

Ni/—N2 N Me (IX) 0 (Vllla)—> e“ o N1 ‘N COzEt NaOEt,DMF F F (IVb) To a solution of intermediate (Vllla) (15.3 g, 44.9 mmol) in DMF (110 mL) cooled to 0°C was added sodium ethoxide (3.13 g, 46.1 mmol) and the mixture stirred at 0°C for 10 min and then treated with the tosylate (IX) (20.2 g, 44.9 mmol). The reaction mixture was d to warm to RT, heated to 50°C for 1 hr and then cooled to RT. Hydrochloric acid (1M, 60 mL) and water (200 mL) were added and the mixture was stirred for 30 min at RT and then extracted with DCM (150 mL). The aq layer was separated and extracted with DCM (2 x 50 mL) and the combined organics were washed with brine (4 x 30 mL) and then dried and evaporated in vacuo to afford a cream solid. The solid was suspended in an equal mixture of isohexanes and IPA (80 mL) and d at RT for 1 hr. The solid was collected by filtration, washed with a mixture of iso-hexanes and IPA 1:1 (3 x 20 mL) and then dried in vacuo at 40°C for 18 hr to afford the title compound, intermediate (IVb) as a white solid (16.4 g, 56%); Rt 2.92 min (Method b); m/z 618 (M+H)+ (ES+); 1H NMR 6: 1.29 (3H, t), 2.10 (3H, s), 2.16 (1H, dd), 2.37- 2.42 (1H, m), 2.52-2.58 (1H, m), 3.12-3.14 (4H, m), 3.43-3.46(4H, m), 3.68 (1H, dd), 3.74-3.79 (2H, m), 4.05 (1H, dd), 4.24 (2H, dd), 4.58 (2H, dd), 6.76 (2H, br s), 6.86 (1H, br s), 6.98-7.05 (3H, m), 7.26-7.34 (2H, m), 7.77 (1H, s), 7.81 (2H, d), 8.34 (1H, s). 1-(((2R,4R)((4-bromomethylphenoxy)methy|)(2,4-difluorophenyl)tetrahydro furanyl)methyl)-1H-1,2,4-triazole.

//—N N\ ) Me N Me (IX) 0 HO Br > 0 Br NaOH, DMSO/HZO F F (XIVa) (XIII) To a solution of 4-bromomethyl phenol (920 mg, 4.89 mmol) in DMSO (10 mL) was added aq sodium hydroxide (0.39 mL, 12.5 M, 4.89 mmol) and the mixture stirred at RT for 10 min and then treated with the tosylate (IX) (2.00 g, 4.45 mmol). The reaction mixture was stirred at 60°C for 72 hr then cooled to RT and partitioned between water (25 mL) and EtOAc (20 mL). The c phase was separated and retained and the aq layer was extracted with EtOAc (3 x 25 mL). The combined organic extracts were washed with brine (3 x 15 mL) and then dried and evaporated in vacuo. The crude product was purified by flash column chromatography (SiOz, 12 g, 0-30% EtOAc in DCM, gradient elution) to give the title compound, intermediate (XIII), as a colourless oil (1.84 g, 86%); Rt 2.78 min (Method a); m/z 464 (M+H)+ (ES+);1H NMR 6: 2.09 (3H, s), 2.17 (1H, dd), 2.37-2.43 (1H, m), 2.52-2.60 (1H, m), 3.72-3.78 (2H, m), 3.82 (1H, dd), 4.00-4.06 (1H, m), 4.57 (2H, dd), 6.82 (1H, d), 7.00 (1H, td), 7.25-7.34 (4H, m), 7.76 (1H, s), 8.34 (1H, s).

Ethyl 4-(4-(4-(((3R,5R)((1H-1,2,4-triazoIy|)methyI)(2,4-difluorophenyl)tetrahydro furanyl)methoxy)methylpheny|)piperaziny|)benzoate.

(XIII) RuPhos,RuPhos G3, wT©7NUN4©7COZE Cszcog, DMF (IVb) A vial charged with ethyl 4-(piperaziny|)benzoate (X) (103 mg, 0.44 mmol), intermediate (XIII) (170 mg, 0.37 mmol), RuPhos (8.5 mg, 18 umol), RuPhos G3 (14.2 mg, 18 umol) and cesium carbonate (191 mg, 0.59 mmol) was ted and backfilled with nitrogen three times before DMF (3.0 mL) was added. The mixture was heated at 80°C for 18 h and then at 100°C for 24 hr. The reaction e was cooled to RT and ioned between water (10 mL) and EtOAc (10 mL). The organic phase was separated and retained and the aq layer was extracted with EtOAc (3 x 10 mL). The combined organics were washed with brine (3 x 10 mL) and then dried and ated in vacuo. The crude product was purified by flash column chromatography (SiOz, 12 g, 0-100% EtOAc in isohexane, nt elution) to give the title compound, intermediate (IVb), as a white solid (100 mg, 43%). 4-(4-(4-(((3R,5R)((1H-1,2,4-triazoly|)methyI)(2,4-difluorophenyl)tetrahydrofuran- ethoxy)methylpheny|)piperaziny|)benzoic acid.

Hydrolysis of the Methyl Ester (IVa) N me LiOH OTGN/—\ (IVa) —> \““‘o \_/N@COZH (ll) DMSO, H20 F F WO 87878 To a suspension of intermediate (lVa) (9.00 g, 14.9 mmol) in DMSO (370 mL) was added a solution of lithium hydroxide (1.79 g, 74.5 mmol) in water (37.0 mL). The mixture was heated at 70°C for 22 hr and was then cooled to RT, diluted with water (1000 mL) and ied (to ~ pH 2) by the addtion of 1M aq hydrochloric acid (80 mL). The mixture was cooled in an ice bath for 2 hr and the resulting precipitate was collected by filtration. The filter cake was washed with water (3 x 80 mL) and dried in vacuo at 50°C to give the title compound, intermediate (II) as a white solid (4.66 g, 54%); Rt 2.21 min d 1a); m/z 590 (M+H)+ (ES+); 1H NMR 6: 2.10 (3H, s), 2.16 (1H, dd), 2.37-2.43 (1H, m), 2.52-2.58 (1H, m), .14 (4H, m), 3.42-3.45 (4H, m), 3.68 (1H, dd), 3.74-3.79 (2H, m), 4.05 (1H, dd), 4.58 (2H, dd), 6.76 (2H, br s), 6.86 (1H, br d), 6.97-7.03 (3H, m), 7.25-7.34 (2H, m), 7.77-7.80 (3H, m), 8.34 (1H, s) and 12.31 (1H, s).

Hydrolysis of the Ethyl Ester (lVb) To a suspension of intermediate (lVb) (16.4 g, 26.6 mmol) in DMSO (375 mL) was added a solution of lithium hydroxide (3.18 g, 74.5 mmol) in water (50 mL). The mixture was heated at 70°C for 22 hr and was then cooled to RT, poured into water (500 mL) and acidified (to ~ pH -6) by the n of 2M hydrochloric acid (70 mL). The mixture was stirred at RT for 30 min and the resulting solid was collected by filtration and washed with water (2 x 20 mL) and with diethyl ether (3 x 30 mL) and then dried in vacuo at 40°C for 18 hr to afford the title compound, ediate (II) as a tan solid (14.2 g, 84%); Rt 2.26 min (Method 1a); m/z 590 (M+H)+ (ES+); 1H NMR 6: 2.09 (3H, s), 2.16 (1H, dd), 2.37-2.42 (1H, m), 2.52-2.58 (1H, m), 3.12-3.14 (4H, m), 3.42-3.44 (4H, m), 3.68 (1H, dd), .79 (2H, m), 4.05 (1H, dd), 4.58 (2H, dd), 6.75 (2H, br s), 6.86 (1H, br s), 6.97-7.03 (3H, m), 7.26-7.34 (2H, m), 7.77-7.80 (3H, m), 8.34 (1H, s), 12.31 (1H, br s). 4-Bromo-N-(4-fluorophenyl)benzamide.

Et3N, DMAP, THF (XIX) (XX) To a on of 4-fluoroaniline (|||) (0.85 mL, 9.00 mmol), triethylamine (1.88 mL, 13.5 mmol) and DMAP (0.11 g, 0.90 mmol) in THF (15 mL) was added 4-bromobenzoyl chloride (XX) (2.37 g, 10.8 mmol). The reaction mixture was maintained at RT for 1 hr and was then partitioned between EtOAc (100 mL) and 1M hydrochloric acid (100 mL). The organic phase was separated and was washed sequentially with 1M hydrochloric acid (100 mL), sat. aq.

NaHCOs (100 mL) and brine (100 mL) and then dried and evaporated in vacuo. The crude residue was triturated from warm DCM (100 mL) and the mixture was heated at reflux to give a white suspension which was allowed to cool to RT. The resulting precipitate was collected by filtration to afford the title compound, intermediate (XIX), as white solid (1.81 g, 65%); Rt 2.23 min; m/z 294/296 (M+H)+ (ES+); 1H NMR 6: 7.20 (2H, t), 7.74-7.79 (4H, m), 7.90 (2H, d) and 10.36 (1H, s). tert-Butyl 4-(4-((4-f|uorophenyl)carbamoyl)pheny|)piperazinecarboxylate.

BocN NH (XII) \_/ O I \ (XIX) —> BocN N w 131@F , RuPhos G3, HN LiHMDS, THF (XVIII) A flask charged with tert—butyl piperazinecarboxylate (Xll) (4.00 g, 215 mmol), intermediate (XIX) (6.63 g, 22.6 mmol), RuPhos (100 mg, 0.215 mmol) and RuPhos G3 (180 mg, 0.215 mmol) was evacuated and lled with en three times. A solution of LiHMDS (1M in THF, 75.0 mL, 75.0 mmol) was added and the reaction mixture was heated at 70°C for 5 hr.

After cooling to RT the e was partitioned n EtOAc (150 mL) and 1M hydrochloric acid (150 mL). The organic phase was separated and retained and the aq phase was ted with EtOAc (3 x 150 mL). The combined organics were dried and concentrated in vacuo to afford a brown solid which was triturated in a mixture of isohexanes and diethyl ether (1:1, 100 mL). The product so obtained was ted by filtration, washed with a e of isohexanes and diethyl ether (1:1, 25 mL) and then dried in vacuo at 40°C to provide the title compound, intermediate (XVIII) as a tan solid (6.44 g, 85%); Rt 2.40 min (Method a); m/z 400 (M+H)+; 1H NMR 6: 1.43 (9H, s), 3.27-3.30 (4H, m), 3.45-3.48 (4H, m), 7.03 (2H, d), 7.14-7.18 (2H, m), 7.74-7.79 (2H, m), 7.88 (2H, d), 9.99 (1H, s).

N-(4-fluoropheny|)(piperaziny|)benzamide. /—\ 0 TFA /—\ o B°°_N “Q4HN®F —> HN NW _ \—/ \ / DCM — HN <\ /> F (XVIII) (XVII) To a solution of intermediate (XVIII) (6.44 g, 16.1 mmol) in DCM (200 mL) was added TFA (24.7 mL, 322 mmol). The reaction was stirred at RT for 2 hr and was then evaporated in vacuo. Toluene (5.0 mL) was added and the mixture was again evaporated in vacuo. The resulting oil was taken up in a mixture of DCM (90 mL) and methanol (10 mL) and was then extracted with a mixture of water (50 mL) and sat. aq NaHCOs (50 mL). The organic phase was separated and retained and the aq layer was extracted with a mixture of DCM and methanol (9:1, 3 x 100 mL). The combined organic layers were dried and concentrated in vacuo to afford the title compound, intermediate (XVII), as a brown solid (3.74 g, 70%); Rt 1.02 min (Method a); m/z 300 (M+H)+; 1H NMR 6: 2.81-2.83 (4H, m), 3.18-3.20 (4H, m), 6.99 (2H, d), 7.14-7.18 (2H, m), 7.74-7.80 (2H, m), 7.85 (2H, d), 9.99 (1H, s).

N-(4-fluorophenyl)(4-(4-methoxymethylphenyl)piperaziny|)benzamide.

MeOQBr (XIVb) Me Me04<\ O (XVII) >7N\—/N4< H RuPhos, RuPhos G3, LiHMDS, THF HN®F (XVI) A flask charged with 4-bromomethoxymethylbenzene (XIVb) (406 mg, 2.02 mmol), intermediate (XVII) (550 mg, 1.84 mmol), RuPhos (43 mg, 0.092 mmol) and RuPhos G3 (77 mg, 0.092 mmol) was evacuated and lled with nitrogen three times. A solution of LiHMDS (9.2 mL, 1M in THF, 9.2 mmol) was added and the reaction mixture was heated at 70°C for 8 hr. After cooling to RT the mixture was quenched by the addition of 1M aq. hydrochloric acid (9.0 mL) and then partitioned between water (15 mL) and EtOAc (15 mL).

The organic layer was separated and retained and the aq layer was extracted with EtOAc (2 x 15 mL). The ed organics were washed with brine (20 mL) and then dried and evaporated in vacuo. The crude product so obtained was purified by flash column chromatography (SiOz, 12 g, 0-100% EtOAc in isohexane, gradient elution) to afford a yellow solid. This material was repurified by flash column chromatography (SiOz, 4 g, 0-10% EtOAc in DCM, gradient elution) to afford the title compound, intermediate (XVI), as an off-white solid (83 mg, 11%); R‘ 2.27 min (Method a); m/z 420 (M+H)+ (ES+); 1H NMR 6: 2.13 (3H, s), 3.13- 3.16 (4H, m), 3.42-3.45 (4H, m), 3.72 (3H, s), 6.77-6.88 (3H, m), 7.08 (2H, d), 7.17 (2H, t), 7.75-7.80 (2H, m), 7.89 (2H, d), 10.02 (1H, s).

N-(4-fluorophenyl)(4-(4-hydroxymethylphenyl)piperaziny|)benzamide.

BBI‘3 /—\ O (XVI) —> Ho N NW DCM 46F (XV) To a suspension of intermediate (XVI) (83 mg, 0.20 mmol) in DCM (5.0 mL) at 0°C was added a solution of boron tribromide (0.59 mL, 1M in DCM, 0.59 mmol). The reaction mixture was stirred at 0°C for 30 min, d to warm to RT for 8 hr and was then ioned between. water (15 mL) and DCM (10 mL). The organic layer was separated and retained and the aq layer was extracted with a mixture of DCM and MeOH (90:10, 5 x 15 mL). The ed organics were dried and evaporated in vacuo to give a crude product which was purified by flash column chromatography (SiOz, 4.0 g, 0-3% MeOH in DCM, gradient elution) to afford the title nd, intermediate (XV), as a beige solid (61 mg, 72%); Rt 1.73 min (Method a); m/z 406 (M+H)+ (ES+); 1H NMR 6: 2.10 (3H, s), 3.08-3.11 (4H, m), 3.41-3.43 (4H, m), 6.67 (2H, br s), 6.77 (1H, br s), 7.07 (2H, d), 7.17 (2H, t), 7.76-7.80 (2H, m), 7.89 (2H, d), 8.73 (1H, s), 10.01 (1H, s). 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)tetrahydrofuran- ethoxy)methylphenyl)piperaziny|)-N-(4-fluorophenyl)benzamide. 1. Preparation of Compound (I) from the Benzoic Acid ediate (ll).

OF /—N ( III ) REV PO 0 (II) \ / QNWNG EDCI, DMAP, Pyridine To a suspension of intermediate (II) (2.50 g, 4.24 mmol), EDCI (1.63 g, 8.48 mmol) and DMAP (30 mg, 0.21 mmol) in pyridine (30 mL) was added 4-fluoroaniline (0.41 mL, 4.3 mmol) and the reaction mixture heated at 60°C for 2 hr and then cooled to RT. Dilution of the mixture with water (60 mL) and stirring for 5 min produced a solid, which was collected by filtration and then washed with water (3 x 10 mL) and with diethyl ether (2 x 15 mL) to give a tan coloured . The crude product so obtained was purified by flash column chromatography (SiOz, 40 g, 0-3% MeOH in DCM, gradient elution) to afford Compound (I) as a yellow solid (2.47 g, 85%); Rt 2.60 min (Method a); m/z 683 (M+H)+ (ES+); 1H NMR 6: 2.10 (3H, s), 2.15 (1H, dd), 2.37-2.43 (1H, m), 2.53-2.58 (1H, m), 3.13-3.16 (4H, m), 3.42-3.44 (4H, m), 3.68 (1H, dd), 3.74-3.79 (2H, m), 4.05 (1H, dd), 4.58 (2H, dd), 6.76 (2H, br s), 6.86 (1H, br s), 6.99 (1H, td), 7.08 (2H, d), 7.16 (2H, t), 7.25-7.35 (2H, m), 7.76-7.80 (3H, m), 7.89 (2H, d), 8.34 (1H, s) and .00 (1H, s). 2. Preparation of nd (I) from the Phenol Intermediate (XV).

F’ : ‘F (Ix) REVM<:\N/—l)\ (XV) —’ //N N\\// <0 NaOH, DMSO/H20 HN <\—/> F To a solution of ediate (XV) (19 mg, 0.047 mmol) in DMSO (1.5 mL) was added aq sodium hydroxide (1M, 98 uL, 0.098 mmol). The mixture was stirred at RT for 10 min and then treated with a solution of tosylate (IX) (ex APlChem, Catalogue Number: AC-8330, 23.2 mg, 0.052 mmol) in DMSO (0.5 mL). The reaction mixture was stirred at 60°C for 2 hr, cooled to RT and water (10 mL) was added. The resulting mixture was extracted with EtOAc (3 x 10 mL) and the combined organic extracts were dried and ated in vacuo to afford a brown oil. The crude product so obtained was purified by flash column chromatography (SiOz, 4 g, 0-2% MeOH in DCM, gradient elution) to afford a beige solid (23 mg). The product was fied by flash column chromatography (SiOz, 4.0 g, 0-50% EtOAc in DCM, gradient n) to afford nd (I), as an off-white solid (14 mg, 42%); Rt 2.60 min (Method a); m/z 683 (M+H)+ (ES+). 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)tetrahydrofuran- 3-yl)methoxy)methylphenyl)piperaziny|)-N-(4-fluorophenyl-2,3,5,6-d4)benzamide.

Preparation of a Tetra-deuterio tive of Compound (I) Fwwzl: N/_\N D D D REV “it?“\ F o / NW0”N 3% (ll)—> \ (I)4[2H1 To a suspension of intermediate (II) (200 mg, 0.34 mmol), EDCI (130 mg, 0.68 mmol) and DMAP (2.1 mg, 0.02 mmol) in ne (1.5 mL) was added a solution of 4-fluoroaniline- 2,3,5,6-d4 (43 mg, 0.37 mmol) in pyridine (0.5 mL) and the reaction mixture heated at 60°C for 1 h. The reaction mixture was cooled to RT, diluted with water (10 mL) and stirred for 5 min, which produced a precipitate. The solid was collected by filtration, washed with water (3 x 2.0 mL) and then taken up in a mixture of DCM and MeOH (9:1, 5.0 mL). The mixture was passed through a phase separator and the organic solution was evaporated in vacuo to give a tan coloured solid (200 mg). The crude product so obtained was purified twice by flash column chromatography (SiOz, 12 g, 0-2% MeOH in DCM, gradient elution; SiOz, 40 g, 0-2.5% MeOH in DCM, gradient elution) to afford an ite coloured .

The solid was suspended in DMSO (0.75 mL) and heated to 60°C for 5 min until dissolution was complete. The resulting solution was cooled to RT and treated with water (1.0 mL) which gave a precipitate. The suspension was stirred at RT for 20 min and the solid was collected by filtration, rinsed with water (3 x 0.5 mL) and dried in vacuo at 50°C or three days) to afford the title compound, (I) 4[2H] as a white solid (147 mg, 62%); Rt 2.59 min d 1a); m/z 687 (M+H)+ (ES+); 1H NMR 6: 2.10 (3H, s), 2.16 (1H, dd), .43 (1H, m), 2.52-2.60 (1H, m), 3.13-3.16 (4H, m), 3.42-3.44 (4H, m), 3.68 (1H, dd), .79 (2H, m), 4.05 (1H, dd), 4.58 (2H, dd), 6.76 (2H, br s), 6.86 (1H, br s), 7.00 (1H, td), 7.08 (2H, d), 7.25-7.35 (2H, m), 7.77 (1H, s), 7.89 (2H, d), 8.34 (1H, s) and 10.01 (1H, s).

Scale-up of the Preparation of nd (I) by Route 2 The synthetic methodology described above for Route 2, (Scheme 1), has been successfully exploited to prepare the compound of the present invention on a scale of over 1.0 kg of API (Scheme 3). Two variants of the methodology have been developed in which the 4-piperazinyl benzoate [Intermediate (V|||)] comprises of either the ethyl ester (Vllla) or the corresponding tert—butyl ester (Vlllb). Both of these compounds may be coupled with the tosylate (IX) to give the corresponding ester precursors to the benzoic acid (II). In the case of the ethyl ester the free acid is obtained by fication, whilst the tert—butyl derivative is de-esterified by acidolysis. The ures adopted for this synthetic campaign are depicted below and are described herein.

Scheme 3: Scale-up of the Synthesis of Compound (I).

H0®Br (XIVa) “'9 N‘ ‘N C02Ra > H0 N \_/N4©7C02Ra RuPhos G3, LiHMDS, DMF (Xa); Ra =Et (Vllla,b) (Xb); Ra=tBu N//—NN NaOEt, DMF — (lVb); Ra: Et KOH’ DMSO, H20 6 (ll); Ra = H <— Conc aq HCI, (Ive); Ra = 1:3" _ IPA, H20 HMO/F NFN HOBt, EDCI, DIPEA Analytical and Spectroscopic Methods The analytical and spectroscopic s pertaining to this experimental section are as set out below.

Reverse Phase HPLC Conditions for LCMS Analysis: XBridge BEH Phenyl 4.6 x 150 mm column; 2.5 pm (Ex. Waters #186006720) at 40°C; flow rate 1.0 mL.min'1 eluted with a purified Hzo-MeCN gradient containing 0.1% formic acid over min employing UV detection at 300 nm. Injection volume 5 uL. nt information: 0-2 min, held at 95% H20-5% MeCN; 2—15 min, ramped from 95% H20-5% MeCN to 10% H20- 90% MeCN; 15-25 min, held at 10% H20-90% MeCN. 1H NMR Spectroscopy: 1H NMR spectra were ted using a JOEL ECX 400MHz spectrometer. Residual undeuterated solvent was used as reference and, unless specified otherwise, samples were run in DMSO-ds.

Ethyl 4-(4-(4-hydroxymethylphenyl)piperaziny|)benzoate.

H0®Br Me /—\ (XlVa) /—\ HN HO N 02Et —> \_/N®C02Et R_uPhos G3, (Xa) LIHMDS, DMF (Villa) A solution of ethyl 4-(1-piperazinyl)benzoate (Xa) (500 g, 2.13 mol) and 4-bromomethyl phenol (479 g, 2.56 mol) in anhydrous DMF (5.0 L) was degassed by placing the e alternately under vacuum and then a nitrogen here three times.The mixture was then treated with RuPhos G3 (35.7 g, 0.043 mol) and a on of LiHMDS (1 .0M in THF, 2560 mL, 2.56 mol) whilst maintaining the al temperature below 35°C (water bath cooling). A solution of LiHMDS (1.0M in THF) was then added in fourteen equal portions at two min intervals (14 x 213 mL, total 2.98 L, 2.98 mol) at 20-35°C. The resulting solution was stirred at 18-25°C for 30 min after which analysis by HPLC indicated 0.6% of the ethyl 4-(1- piperazinyl) benzoate remained the reaction was deemed complete.

The reaction mixture was adjusted to pH 7.6 by the addition of 2M hydrochloric acid (5.50 L) whilst maintaining the temperature below 40°C, after which EtOAc (3.00 L) was added and the resulting phases separated. The aq phase was extracted with EtOAc (2 x 3.00 L and then 2 x 2.00 L) and the combined organics were washed with sat brine (8 x 1.00 L), dried over MgSO4 and then evaporated in vacuo to give a light brown oily solid. The crude product was slurried in IPA (2.50 L) at 20-25°C for 30 min and the resulting solid was ted by filtration.

The filter cake was washed with IPA (2 x 500 mL) and pulled dry and the solids then dried under vacuum at 50°C to provide the title compound, intermediate (Vllla), as a light tan solid (380.0 g, 52%, HPLC purity ; Rt 11.01 min; m/z 341.3 (M+H)+ (ES+).

In order to control the level of palladium residues, the products from several batches were combined (1900 g, residual Pd 108 ppm), taken up into THF (19.0 L) and treated with MP- TMT resin (250 g) at 18-25°C. The mixture was stirred at this temperature for 24 hr and the resin was then removed by filtration and washed with THF (3.49 L). The filtrate was evaporated to dryness in vacuo and the resulting solid was slurried in IPA (4.75 L) at C for 1 hr and collected by filtration. The filter cake was washed with IPA (500 mL), pulled dry and was then dried in vacuo at 50°C to give the title compound, intermediate (Vllla), as an off-white solid (1789 g, 94%, residual Pd 17 ppm).

Ethyl 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)-tetrahydro furanyl)methoxy)methylphenyl)piperazinyl)benzoate.

HO N N COzEt (Vllla) F'1' (IX) NaOEt, ”\N 0 Me 0 N N COzEt F F ( IVb) To a solution of intermediate (Villa) (1780 g, 5.23 mol) in anhydrous DMF (17.8 L) at C was added sodium ethoxide (391 g, 5.75 mol). After 45 min the tosylate (IX) (2586 g, 5.75 mol) was added in one portion and stirring was continued at C for 5 hr. Analysis by HPLC indicated that the on was essentially complete (1.67% starting material remaining).

The mixture was cooled to 18-25°C and the resulting suspension was treated with water (18.0 L) whist ining the temperature below 30°C. After cooling to 15-25°C for 45 min the solid was collected by filtration and washed with water (2 x 7.14 L). The damp filter cake was slurried in ethanol (8.92 L) at reflux for 2 hr and the mixture was then cooled to 15-25°C and stirred for 18 hr. The solids so ed were collected by filtration, washed with l (2 x 1.78 L) and then dried in vacuo at 50°C to provide the title compound, intermediate as an off- white solid (2855 g, 88%, HPLC purity 95.97%); Rt 14.99 min; m/z 618.5 (M+H)+ (ES+). 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)-tetrahydrofuran yl)methoxy)methylphenyl)piperazinyl)benzoic acid mono-hydrochloride.

N\ B 0 Me 00FM»<IVb> ; Ra: Et — (u); Ra : H DMSO, H20 F F To a suspension of intermediate (lVb) (1467 g, 2.38 mol) in mixture of DMSO (1.45 L) and water (5.90 L) at 18-25°C was added a 50% w/w solution of KOH in water (2.93 L). The suspension was heated at 90-95°C for 18 hr after which time HPLC analysis indicated that the reaction was complete (0.16% starting material remaining, 97.9% product). The reaction mixture was cooled to 40-50°C and a mixture of IPA (14.9 L) and water (4.42 L) was added.

After cooling to 15-25°C, the pH was adjusted to 1-2 by the on of concentrated hloric acid (3.12 L) whilst maintaining the internal temperature below 40°C. The resulting suspension was cooled to 15-25°C and the solids were collected by filtration, pulled dry and then slurried in water (7.40 L) at 90-95°C for 30 min. After cooling to 15-25°C, the solids were collected by filtration, washed with water (2 x 1.48 L) and pulled dry. Further drying in vacuo at 50°C yielded the title compound, intermediate (II), as a white solid (1329 g, 89%, HPLC purity 99.0%; chlorine content: 6.61 w/w % [theory 5.66 w/w %]; Rt 12.92 min; m/z 590.4 (M+H)+ (ES+). tert-Butyl 4-(4-(4-hydroxymethylphenyl)piperaziny|)benzoate. :>%—Br Me ::>—cogBu (xwh) /—\ HN 44444444444» HO N x_/ x_/N—<::>—co;Bu RuPhos G3, (Xb) LiHMDS, DMF (Vlllb) A solution of utyl 4-(piperaziny|)benzoate (Xb) (100 g, 381 mmol) and 4-bromo methylphenol (85.5 g, 457 mmol) in anhydrous DMF (1.00 L) was degassed by placing the mixture alternately under vacuum and then a nitrogen atmosphere three times. Following this procedure, RuPhos G3 (6.38 g, 7.62 mmol) was added at 15-25°C followed by a solution of LiHMDS in THF (1.06 M, 432. mL, 457 mmol) over 5 min whilst maintaining the temperature within 15-30°C, (water bath cooling). After stirring for 5 min additional aliquots of the solution of LiHMDS (1.06 M in TH F) was added to the reaction mixture in en equal portions (14 x 36 mL, total 504 mL, 533 mmol) at 2 min intervals, resulting in an exotherm from 16°C- he reaction was stirred at 15-25°C overnight (at which point HPLC showed the formation of 72.% of the d product) and the pH of the mixture was adjusted to 7.3 by the addition of 2M hydrochloric acid (~900 mL). The aq phase was ted and was extracted repeadtedly with EtOAc (1.0 L, 500 mL and 2 x250 mL). The combined organics were washed with brine (6 x 400 mL), dried over MgSO4 and concentrated in vacuo to give a sticky yellow solid. The solid so obtained was suspended in IPA (500 mL) and was stirred at 15-25°C for 1 hr. The suspension was filtered and the filter cake was washed with IPA (250 mL, 200 mL) and pulled dry. Further drying of the product in vacuo at 50°C provided the title compound, intermediate (Vlllb) as an off-white solid (105.6 g, 75%, HPLC purity 97.1%); Rt 12.23 min; m/z 369.3 (M+H)+ (ES+) tert-Butyl 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)—tetra hydrofuranyl)methoxy)—3-methylphenyl)piperaziny|)benzoate.

’ ‘ HO N N C02 But (vmb) MTKN 0X) N NaOEt DMF 0 Me ’ ‘ o N N cmBut F F (We) WO 87878 To a solution of intermediate (Vlllb) (100 g, 271 mmol) in DMF (500 mL) under a nitrogen atmosphere was added sodium de (22.2 g, 325 mmol) resulting in a mild exotherm (from to 220°C). After stirring at 15-25°C for 45 min the reaction mixture was treated with the tosylate (IX) (146.4 g, 325 mmol) and was then heated at 60-65°C for 2 hr. Analysis of the resulting mixture by HPLC indicated that the reaction was essentially complete (4.4% phenol remaining, 14.6% tosylate, 77.6% product) and the mixture was cooled to 40-45°C and IPA (800 mL) was added. Water was then added drop-wise at 40-45°C until a slight haze persisted (required 500 mL) at which point a small sample of the product (100 mg, 0.15 mmol) was added as a seed and the mixture stirred for 10 min at 40-45°C to ensure precipitation was initiated. Water (500 mL) was added drop-wise at 40-45°C and the suspension then cooled to -25°C. The resulting solid was collected by filtration, washed with water (3 x 200 mL) and then dried in vacuo at 50°C give the crude product as an off-white solid (155.9 g, 89%, HPLC purity 94.8%). A n of this material (85.0 g) was taken up in IPA (510 mL) by heating at 65-75°C until dissolution was te. The solution was then cooled to 15-25°C and stirred for 30 min. The resulting solid was collected by filtration, washed with IPA (2 x 85 mL) and dried in vacuo at 50°C to give the title compound, intermediate (IVc) as a white solid (83.4g, 87% overall yield, HPLC purity 98.2%); Rt 15.74 min; m/z 646.6 (M+H)+ (ES+) 4-(4-(4-(((3R,5R)((1H-1,2,4-triazoly|)methy|)(2,4-difluorophenyl)-tetrahydrofuran y|)methoxy)methylphenyl)piperaziny|)benzoic acid mono-hydrochloride.

N//—N — (IVc), Ra: Conc aq HCI, 0 4» (u); Ra: H (HCI salt) To a suspension of the tert—butyl te (IVc) (83.4 g, 129 mmol) in a mixture of water (250 mL) and IPA (417 mL) was added a solution of conc hydrochloric acid (167 mL) in water (167 mL) whilst maintaining the al temperature below 35°C. The resulting on was then kept at 35°C for 24 hr (solid formation observed after 2-3 hr) at which point HPLC is indicated the reaction was essentially complete (0.6% ester remaining, 98.1% product) The mixture was cooled to 15-25°C, IPA (417 mL) was added and the pH was adjusted ~10 by the addition of aq NaOH (10 M, 200 mL) at <40°C to give a solution. The pH was then re-adjusted to 1-2 by the on of conc hydrochloric acid (25 mL) at <40°C. The resulting suspension was cooled to 15-25°C and the solids were collected by filtration. The filter cake was resuspended in water (834 mL), heated to C and then stirred for 30 min. The suspension was then cooled to 15-25°C and the solids collected by filtration, washed with water (2 x 83 mL) and dried in vacuo at 50°C to provide the title compound, intermediate (II), (as the mono-hydrochloride salt) as a white solid (64.6 g, 80%, HPLC purity 97.6%); Rt 12.92 min; m/z 590.4 (M+H)+ (E9).

C:\Interwoven\NRPortbl\DCC\BAS\19270341_1.docx-04/09/2019 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4-difluorophenyl)-tetrahydrofuran methoxy)methylphenyl)piperazinyl)-N-(4-fluorophenyl)benzamide.

To a stirred suspension of the benzoic acid (II) as its mono-hydrochloride salt (1001 g, 1.60 mol) and HOBt.H2O (216. g, 1.41 mol) in DMF (5020 mL) at <40°C was added DIPEA (840 mL, 4.823 mol) followed by 4-fluoroaniline (181 mL, 1.91 mol) and then EDCI.HCl (368 g, 1.92 mol). The mixture was heated at 60-65°C for 17 hr at which time analysis by HPLC indicated the reaction was te (no starting material or reaction intermediate detected, 82.63% product). The resulting solution was cooled to 15-25°C and was quenched with water (15.2 L) at <35°C, then cooled again to 15-25°C and stirred for 1 hr. The resulting solid was ted by filtration, washed with water (2 x 2.00 L) and pulled dry. The filter cake was re-slurried in water (5.00 L) at 15-25°C for 45 min and the solids were collected by filtration, washed with water (2 x 2.00 L) and dried in vacuo to afford the title compound, Compound (I), as an offwhite solid (1101 g, ~100%, HPLC purity 95.8%); Rt 14.46 min; m/z 683.5 (M+H)+ (ES+); 1H NMR δ: 2.10 (3H, s), 2.16 (1H, dd), 2.37-2.43 (1H, m), 2.50-2.58 (1H, m), 3.13-3.15 (4H, m), 3.41-3.44 (4H, m), 3.67 (1H, dd), 3.74-3.78 (2H, m), 4.05 (1H, t), 4.55 (1H, d), 4.61 (1H, d), 6.76 (2H, s), 6.86 (1H, s), 7.00 (1H, d,t), 7.08 (2H, d), 7.17 (2H, t), .35 (2H, m), 7.76- 7.80 (2H, m), 7.77 (1H, s), 7.89 (2H, d), 8.35 (1H, s) and 10.02 (1H. S).

Biological Testing: Experimental s Assessment of planktonic fungus growth a. Resazurin-microtitre assay This assay was conducted using a modified, published method (Monteiro et al., 2012). Spores of illus fumigatus (NCPF2010, Public Health England, Wiltshire) were cultured in Sabouraud dextrose agar for 3 days. A stock spore suspension was ed from a Sabouraud dextrose agar culture by washing with PBS-tween (10 mL; PBS containing 0.05% Tween-20, 100 U/mL Penicillin and 100 U/mL Streptomycin). The spore count was assessed using a Neubauer haemocytometer and, using PBS, adjusted to 106 spores/mL. A working suspension of spores (104 spores/mL) was prepared in filter sterilised MOPS RPMI-1640 (50 mL; RPMI-1640 containing 2 mM amine, 2% glucose and 0.165 M MOPS, buffered to pH 7 with NaOH). rin sodium salt (100 µL of 1% solution; Sigma-Aldrich, Dorset, UK) was added to the spore suspension and mixed well. The spore suspension-resazurin mixture (100 uL/well) was added to 384-well plates (Catalogue number 353962, BD Falcon, Oxford, UK). Simultaneously, test nds (0.5 uL DMSO solution) were added to 100 uL of the spore-resazurin mixture in quadruplicate to provide a final DMSO solution of 0.5% using an lntegra VlAFLO 96 (lntergra, Zizers, Switzerland). For non-spore control wells, MOPS-RPMI- resazurin solution (100 uL) was added instead of the spore-resazurin mixture. The plate was covered with a Breathe Easier membrane (Catalogue No Z763624, Sigma-Aldrich, Dorset, UK), and incubated (35°C, 5% C02) until fluorescence in the inoculated wells was double that of the control wells (around 24 hr). The fluorescence of each well (545 nm (excitation) / 590 nm (emission), gain 800, focal height 5.5mm) was determined using a scanner (Clariostar: BMG, Buckinghamshire, UK). The tage inhibition for each well was calculated and the MIC50, M|C75 and MIC90 values were calculated from the concentration- se curve generated for each test compound. b. Broth microdilution assay This assay was conducted using a modified method published by EUCAST (Rodriguez- Tudela et al., 2008). Spores of Aspergi/Ius tus (NCPF2010, NCPF7010 (Methionine 220 mutation), 99 ne G54 mutation) from Public Health England, Wiltshire; TR34/L98H mutants from St Louis Hospital, Paris, France) were cultured in Sabouraud dextrose agar for 3 days. A stock spore suspension was prepared from a Sabouraud dextrose agar culture by washing with een (10 mL; PBS containing 0.05% Tween-20, 100 U/mL llin and 100 U/mL Streptomycin). The spore count was assessed using a Neubauer haemocytometer and then adjusted to ‘106 /mL with PBS. A working suspension of spores (2 x ‘105 spores/mL) was prepared in filter sterilised, BSA MOPS RPMl-1640 (50 mL; RPMl-1640 containing 2 mM L-glutamine, 0.5% BSA, 2% glucose, 0.165 M MOPS, buffered to pH 7 with NaOH). Forthe assay, BSA MOPS RPMl-1640 (50 uL/well) was added throughout the 384-well plate (Catalogue number 353962, BD Falcon, Oxford, UK) first. Test compounds (0.5 uL DMSO solution) were then added in quadruplicate using an a VlAFLO 96 (lntegra, Zizers, Switzerland), and mixed well using a plate mixer. Subsequently 50 uL of the working spore suspension prepared above was added to all wells except non-spore control wells. For non-spore control wells, BSA PMI on (50 uL/well) was added d. The plate was covered with a plastic lid, and incubated (35°C with ambient air) for 48 hr. The OD of each well at 530 nm was determined using a multi-scanner (Clariostar: BMG, Buckinghamshire, UK). The percentage inhibition for each well was calculated and the MIC50, M|C75 and MIC90 values were calculated from the concentration-response curve generated for each test Fungus panel screening was conducted by Eurofins Panlabs Inc. The MIC and M|C5o values 40 of the test articles were ined following the guidelines of the Clinical and Laboratory Standards Institute, broth microdilution methods for yeast (CLSl M27-A2), (CLSI, 2002) and for filamentous fungi (CLSl M38-A), (CLSI, 2008).

Aspergillus fumigatus infection of ial epithelial cells BEAS2B cells were seeded in 96-well plates (100 uL; 30,000 cells /we|l; Catalogue No 3596, Sigma Aldrich, Dorset, UK) in 10% FBS RPMl-1640 and were then incubated (37°C, 5% CO2) for one day before experimentation. Test compounds (0.5 uL DMSO on) or vehicle (DMSO) were added to each well to give a final DMSO concentration of 0.5%. BEAS2B cells were incubated with test compounds for 1 hr (35°C, 5% C02) before infection with Aspergillus fumigatus (20 uL; Public Health d) conidia suspension (0.5x105 /ml in 10% FBS RPMI- 1640). The plate was incubated for 24 hr (35°C, 5% C02). Supernatant (50 uL) was collected and transferred to a PCR plate (Catalogue No L1402-9700, Starlab, Milton Keynes, UK), which was frozen ) until use. After thawing, supernatant (5 uL) was d 1:20 by adding R7- PBS solution (95 uL; 1:4 R7 to PBS; Bio-Rad Laboratories, Redmond, WA, USA). GM levels in these samples (50 uL) were measured using Platelia GM-EIA kits ad Laboratories, Redmond, WA, USA). The tage inhibition for each well was calculated and the |C5o value was calculated from the concentration-response curve generated for each test compound.

Aspergillus fumigatus infection of human alveoli bilayers In vitro models of human alveoli, consisting of a bilayer of human alveolar lial cells and endothelial cells, were ed as usly described (Hope et al., 2007). This system allows administration of a test nd to the upper (“air” space) and/or lower (“systemic” space) compartments. This flexibility has been exploited to explore the effects of combination treatments by dosing Compound (I) to the upper chamber and posaconazole or other anti- fungal agents to the lower chamber. Primary human pulmonary artery endothelial cells (HPAEC) were harvested and diluted to 106 cells/mL in EGM-2 media (Lonza, Basel, Switzerland). Transwells were inverted and the cell suspension (100 uL/well) was applied to the base of each transwell. The inverted transwells were incubated at RT within a flow hood for 2 hr after which they were turned upright. EGM-2 media was added to the lower (700 uL/well) and upper (100 uL/well) compartments and the transwells were incubated for 48 hr (37°C, 5% C02). The EGM-2 media in the lower compartment was then replaced with fresh EGM-2 media. A549 cells were ted and diluted to 5x105 cells/mL in 10% EBM, then added to the upper compartment (100 l) of all transwells and the plates incubated for 72 hr (37°C, 5% C02). Conidia of Aspergillus fumigatus (the itraconazole sensitive strain NCPF2010 and the itraconazole resistant strain TR34-L98H) were cultured separately in Sabouraud dextrose agar for 3 days. A stock conidia suspension of either strain was prepared from a Sabouraud dextrose agar culture by washing with PBS-tween (10 mL; PBS containing 0.05% Tween-20, 100 U/mL Penicillin and 100 U/mL Streptomycin). The conidia count was assessed using a Neubauer haemocytometer and ed to 106 conidia/mL with PBS. A 40 working stock of conidia was prepared in EBM (cone of 105 conidia/mL) immediately prior to use.

Test and nce compounds (or neat DMSO as the vehicle) were added to the appropriate wells of 24-well plates (3 uL/well ning 600 uL of 2% FBS EBM) for lower compartment 2015/053731 treatment and to 96-well plates (1 uL/well ning 200 uL of 2% FBS EBM) for the ent of the upper tment, to provide a final DMSO concentration of 0.5%. The media in the upper compartment was aspirated and that containing the riate test and reference compounds, or vehicle, were added (100 uL/well). Transwells were then transferred into the 24-well plate containing the test and reference compounds or DMSO vehicle. After tion for 1 hr (35°C, 5% C02) the conidia suspension (10 uL/well) was added to the upper compartment of each transwell. Plates were then incubated for 24 hr (35°C, 5% C02).

Supernatants from each compartment (5 uL/compartment) were collected and stored (-20°C).

Media was replaced daily after collection of the supernatants and all wells were treated with test and reference compounds or with DMSO, as described above, for 3 days. Samples continued to be collected until fungal growth was visible by eye in all transwells. The levels of GM in the supernatant in lower compartment were then measured by ELISA (BioRad, CA, USA) as an index of Aspergillus fumigatus invasion.

Cell Viability: Resazurin Assay BEAS2B cells were seeded in 384-well plates (100 uL; 3000 / well /; BD Falcon, Catalogue No 353962) in RPMl-LHC8 (RPMl-1640 and LHC8 media combined in equal proportions) one day before experimentation. For cell-free control wells, RPMl-LHC8 (100 uL) was added. Test compounds (0.5 uL of a DMSO solution) were added to give a final DMSO tration of 0.5% using an lntegra VIAFLO 96 (lntegra, Zizers, rland). BEAS2B cells were incubated with each test compound for 1 day (37°C / 5% COzin RPMl-LHC8). After addition of resazurin stock solution (5 uL, 0.04%) the plates were incubated for a further 4 hr (37°C / 5% C02). The fluorescence of each well at 545 nm (excitation) and 590 nm (emission) was determined using a multi-scanner (Clariostar: BMG Labtech). The percentage loss of cell viability was calculated for each well relative to vehicle (0.5% DMSO) treatment. Where appropriate, a CC5o value was ated from the concentration-response curve ted from the concentration-response curve for each test compound.

In Vivo Anti-fungal Activity Aspergillus fumigatus (ATCC 13073 [strain: NIH 5233], American Type Culture Collection, Manassas, VA, USA) was grown on Malt agar (Nissui Pharmaceutical, Tokyo, Japan) plates for 6—7 days at RT (24 1r 1°C). Spores were aseptically dislodged from the agar plates and suspended in sterile distilled water with 0.05% Tween 80 and 0.1% agar. On the day of infection, spore counts were assessed by haemocytometer and the inoculum was adjusted to obtain a concentration of 1.67 x 108 spores mL'1 of physiological saline.

To induce immunosuppression and penia, A/J mice (males, 5 weeks old) were dosed 40 with hydrocortisone (Sigma H4881; 125 mg/kg, sc,) on days 3, 2 and 1 before infection, and with cyclophosphamide (Sigma C0768; 250 mg/kg, ip) 2 days before ion. On day 0, animals were infected with the spore suspension (35 uL intra-nasally).

Test nds were administered intra-nasally (35 uL of a suspension of 0.08-2.00 mg/mL 45 in physiological saline) once daily, 30 min before infection on day 0 and then on days 1, 2 and 3 (representing prophylactic treatment) or on days 1, 2 and 3 only senting therapeutic treatment). For extended prophylactic treatment, test compounds (35 uL of a suspension of 0.0032 or 0.016 mg/mL in physiological saline) were administered nasally once daily for seven days; then 30 min before infection on day 0, and thereafter, either on days 1, 2 and 3 after infection, or on day 0 only. The effects of these treatment paradigms were compared with those obtained when treatment was restricted to one day and 30 min before inoculation and then on days 1, 2 and 3 post infection; or reduced still further to one day and 30 min before infection only. Animal body s were monitored daily and those exhibiting a reduction 220%, compared with their body weight on day 0, were culled.

Six hours after the last dose, animals were etised, the a was cannulated and BALF was collected. The total number of alveolar cells was determined using a haemocytometer, and the numbers of alveolar macrophages and neutrophils were determined by FACS analysis (EPICS® ALTRA ll, Beckman Coulter, lnc., Fullerton, CA, USA) using anti- mouse MOMA2-FITC (macrophage) or anti-mouse 7/4 (neutrophil), respectively, as previously reported (Kimura et a/., 2013). The levels of lFN-y and lL-17 in BALF, and lL-6 and TNFo in serum were determined using Quantikine® mouse lFN-y, lL-17, lL-6 or TNF-d ELISA kit (R&D systems, Inc, Minneapolis, MN, USA) respectively. MDA, an ive stress marker, was assayed using OxiSelect® TBARS Assay Kits (MDA Quantitation; Cell Biolabs Inc, San Diego, CA, USA). Aspergillus GM in serum was determination using Platelia GM-EIA kits (Bio-Rad Laboratories, Redmond, WA, USA). Cut-off index was calculated by the a: Cut-off index = OD in sample / OD in cut-off control provided in kit. For tissue fungal load assays, 100 mg of lung tissue was removed aseptically and homogenized in 0.2 mL of 0.1% agar in sterile distilled water. Serially diluted lung homogenates were plated on Malt agar plates (50 uL/plate), and ted at 24i1°C for 72 to 96 h. The colonies of A. fumigatus on each plate was counted and the fungal titre presented as CFU per gram of lung tissue.

Severely immunosuppressed, neutropenic A/J mice (males, 5 weeks old), which had been dosed with hydrocortisone (Sigma H4881; 125 mg/kg, sc,) daily for three days before infection and with cyclophosphamide (Sigma C0768; 250 mg/kg, ip) two days before ion were used to evaluate the s of the combined treatment of Compound (I) administered intranasally and posaconazole dosed orally. On day 0, s were infected intranasally with uL of the spore suspension (1.67 x 108 spores/mL in logical saline) of Aspergillus fumigatus (ATCC 13073 [strain: NIH . Compound (I) prepared as a suspension in isotonic saline (0.4 mg/mL) was dosed once daily by an intra-nasal injection (35 uL/mouse) on days 1-6 after infection. Posaconazole (1 mg/kg) was given orally once daily on days 1-6 after infection. Body weight and survival were monitored daily up to day 7. y of Screening Results Compound (I) demonstrates potent inhibitory activity against both azole sensitive Aspergillus fumigatus fungal growth, as evaluated by the resazurin assay, and fungal infection of bronchial epithelial cells (Table 2). In these assay s Compound (I) showed significantly greater potency than nazole and amphotericin B, and similar potency to posaconazole.

Incubation with Compound (I) had no or little effect on the viability of BEAS2B bronchial epithelial cells at concentrations up to, at least, 10 uM.

Table 2 The effects of treatment with Voriconazole, Posaconazole, ericin B and Compound (I) on Aspergi/lus fumigatus (NCPF2010) planktonic fungal growth, on fungal infection of BEAS2B ial epithelial cells and on BEAS2B cell viability.

Mlcso I MIC75 I CC50 Values in assay system indicated (nM) Planktonic fungal Infection of BEASZB Treatment growth1 BEAS2B cells2 Cell Viability3 (Test Compound) MIC50 MIC75 MIC50 CC50 Voriconazole 90.8 168 154 >28600 Posaconazole 3.64 6.94 4.48 >14300 Amphotericin B 28.5 64.4 nt 977 Compound (I) 1.98 5.02 5.43 >12200 Compound (l).4[2H] nt nt 3.15 >14600 Table Footnotes: 1. Resazurin-microtitre assay; 2. Bronchial lial cells; 3. n = 1-5; Compound (I) also exhibits potent inhibitory activity against onic fungal growth as evaluated in a broth microdilution assay (Table 3). In this assay, Compound (I) showed significantly greater potency versus both posaconazole-resistant strains (NCPF7099, NCPF7100 and TR34/L98H) and a posaconazole-sensitive strain (NCPF2010) than posaconazole, voriconazole and Amphotericin B.

Table 3 The Effects of ent with Voriconazole, Posaconazole, Amphotericin B and Compound (I) on planktonic fungal growth of es of Aspergi/lus fumigatus.

MIC75 Values (nM) Treatment t the indicted Aspergillus fumigatus isolates1 (Test nd) NCPF2010 NCPF7099 NCPF7100 L98H Voriconazole 496 96.7 596 >2860 Posaconazole 15.3 112 71.5 150 Amphotericin B 382 365 >1080 209 Compound (I) 13.6 16.5 19.7 56.7 Compound (l).4[2H] 14.7 13.7 28.6 70.0 Table tes: 1. Broth microdilution assay, n =1-3 The s of Compound (I) on the growth of wide range of fungal pathogens were ted using the CLSI broth microdilution methods. Compound (I) was found to be a potent inhibitor of the growth of Rhizopus oryzae, Cryptococcus neoformans, Chaectomimum globosum, Penicillium chrysogenum and Trichophyton rubrum as well as some Candida Spp (Table 4).

Table 4 The effects of Compound (I) on the growth of a range of fungi species.

Compound (I) Voriconazole Posaconazole Fungal Mleo MlC1oo Mleo M|C1oo Mleo M|C1oo Strain_ Agent (Hg/mL) (Hg/mL) (Hg/mL) Aspergi/lus ATCC204304 1.0 >8.0 1.0 2.0 0.063 0.13 flavus Aspergi/lus ATCC9348 >80 >80 >80 >80 0.25 1.0 pul/u/ans 20240.04? 0.031 >8.0 0.031 >8.0 0.031 >8.0 ATCC10231 0.13 >8.0 0.25 >8.0 0.13 >8.0 Candida_ albicans 20183.073 0.5 >8.0 4.0 >8.0 0.25 >8.0 20186.025 >80 >80 >8 0 >8 0 >8 0 >8 0 ATCC36583 0.5 >8.0 0.25 >8 0 0.5 >8.0 Candida_ glabrata R363 0.5 >8.0 >8 0 >8 0 0.5 >8.0 Rhizooryzgeus ATCC11145 0.063 2.0 8.0 >8.0 0.13 >8.0 forman:tococc s ATCC24067 0.008 1.0 0.016 1.0 0.016 0.25 mium ATCC44699 0.063 >8.0 0.5 1.0 0.13 0.25 globosum Penicillium ATCC9480 0.031 >8.0 1.0 2.0 0.063 0.13 chrysogenum Trichophyton 218 <0.008 0.031 <0.008 0.063 <0.008 0.031 rubrum Table footnotes: MICso/ M|C1oo = concentration required for 50% and 100% tion of fungal growth by visual inspection (CLSI).

Monotherapy with either Compound (I) (0.1 ug/mL in the upper chamber) or posaconazole (0.01 ug/mL in the lower chamber) inhibited GM production on day 1 in human alveoli bilayers.

However, the inhibitory effects of these treatments were lost rapidly thereafter (Table 5). In contrast, combination treatment of Compound (I) with posaconazole showed sustained inhibition of invasion post infection. Consequently, the DFB5o for the combination treatment was 5.48 days, much longer than the values for either compound alone. This synergistic or additive effect of combination therapy was also confirmed when treatment with Compound (I) was combined with that of onazole, voriconazole or caspofungin (results not shown).

Table 5 Effects of Compound (I), Posaconazole and the ent combination on Aspergi/Ius fumigatus (NCPF2010) invasion into the lower r in human alveoli bilayers (transwells).

GM Levels in the Lower Chamber for Treatments Indicated OD value (% inhibition vs.control)l Treatment nd (I)1 Posaconazole2 Combination Vehicle Day Upper Chamber Lower Chamber Treatment 0 0 0 0 0 1 0.68 0.091 (86) 0.064 (91) 0.007 (99) 2 1.19 1.15 (3.4) 1.01 (15) 0.011 (99) 3 1.19 1.14 (3.7) 1.14 (4.1) 0.025 (98) 4 1.18 1.13 (4.5) 1.17 (1.1) 0.11 (91) 1.18 1.18 (0.3) 1.18 (-0.6) 0.42 (64) 6 1.18 1.18 (-0.3) 1.19 (-1.1) 0.73 (38) 7 1.18 1.16 (0.9) 1.17 (0.3) 1.15 (2.0) 8 1.16 1.13(2.8) 1.15(0.8) 1.12(3.7) DFBso Values for 1'13 1-45 5.48 treatments indicated Table footnotes: 1. Dosed at 0.1 ug/mL; 2. Dosed at 0.01 ug/mL; DFBso: Days taken to reach a fungal burden of 50% of control In on, this combination treatment has been tested in bilayers ed with the azole resistant strain of Aspergi/Ius fumigatus: TR34-L98H. (Table 6) Monotherapy with Compound (I) (1 ug/mL) in the upper chamber or with posaconazole (0.1 ug/mL) in the lower chamber showed limited benefit. In st, the combination of Compound (I) and posaconazole showed marked tory effects on fungal invasion into the lower chamber. The beneficial effect of the combination treatment was observed on day 1 post infection, but disappeared after day 2.

Table 6 Effects of nd (I), Posaconazole and the treatment combination on Aspergi/lus fumigatus (TR34-L98H strain) invasion into the lower chamber in the alveolar bilayer cell system (transwells).

GM Levels in the Lower Chamber for Treatments Indicated OD value (% inhibition vs.control)l Compound (I)1 Posaconazole2 Combination Treatment Day Upper r Lower Chamber Treatment 0 0 0 0 1 0.35 0.039 (88) 0.013 (96) 2 0.99 1.02 (-2.7) 0.082 (92) 3 0.99 0.97 (1.7) 0.54 (45) 4 1.01 1.02 (-1.4) 1.09 (-8.8) DFB“ va'ues f°r 1.10 1.64 2.93 treatments indicated Table footnotes: 1. Dosed at 1 ug/mL; 2. Dosed at 0.1 ug/mL; DFBso: Days taken to reach a fungal burden of 50% of control When given intranasally to immunocompromised, neutropenic mice, on days 0 and 1-3 following innoculation (Prophylactic Treatment) in a head-to-head comparison, nd (I) showed superior s to posaconazole on reducing body weight loss, measured over 3 days, caused by infection with Aspergi/lus fumigatus. (Table 7).

Table 7: Comparison of the Effects of Treatment with Compound (I) and Posaconazole on the body weight loss of compromised, neutropenic mice caused by infection with Aspergi/lus fumigatus.

Body weight loss caused by ion with A. fumigatus2 Drug (% Inhibition of weight loss) Treatment1 Day 1 Day 2 Day 3 Vehicle plus Spores 9.2 1r 1.5 14.3 1r 1.9 19.3 1r 1.4 Posaconazole 7.3 1r 2.0 (21) 13.4 1r 1.9 (6) 18.1 1r 2.0 (6) Compound (I) 6.1 1r 1.8 (34) 8.7: 2.5 (39) 11.1 1r 5.6 (42) Table footnotes: 1. Dosed at 0.4 mg/mL intra-nasally; 2. % weight loss compared with animal weight on day 0.

Furthermore, prophylactic and therapeutic treatment with Compound (I), showed superior effects to posaconazole on fungal load in the lung, as well as on GM trations in both BALF and serum, post infection. The data for Compound (I) used in prophylactic and therapeutic dosing regimens are shown in Table 8 and Figs. 1, 2 and 3 (lD5o values presented in Table 9).

Table 8: The Effects of Prophylactic and Therapeutic Treatment with Compound (I) on CFU in lung and galactomannan concentrations in BALF and serum in i/Ius fumigatus infected, immuno-compromised, neutropenic mice.

% Inhibition of response Drug Treatment Conc Regimen CFU GM in BALF GM in serum (mglmL) (lmg of lung) (COI) (COI) veh'c'e + None 28.4 i 16.9 4.8 i 0.40 5.3 i 1.1 Spores 0.08 15.2 1r 13.7 (46) 0.70 1r 0.39 (85) 0.81 1r 0.52 (85) Compound (I): lactic 0.4 2.1 1r 1.6 (93) 0.37 1r 0.46 (92) 0.24 1r 0.18 (95) Treatment 2 0.8 1r 0.7 (97) 0.13 1r 0.02 (97) 0.18 1r 0.07 (97) 0.4 3.8 1r 1.0 (87) 0.24 1r 0.06 (95) 0.29 1r 0.11 (95) Compound (I): Therapeutic 2 1.9 1r 1.7 (93) 0.22 1r 0.14 (95) 0.25 1r 0.19 (95) Treatment 0.5 1r 0.3 (98) 0.11 1r 0.05 (98) 0.24 1r 0.11 (95) Table footnotes: The data for fungal load are shown as the mean i standard error ofthe mean (SEM; n = 5-6).

Table 9: |D5o values for Prophylactic Treatment with Posaconazole and nd (I) on fungal load in the lung and on galactomannan concentrations in BALF and in serum, in Aspergi/Ius fumigatus infected, immuno-compromised, neutropenic mice.

Drug substance IDso Values for response indicated (mglmL) ylactic Regimen) Lung Fungal Load GM in BALF GM in serum Compound (I) 0.086 <0.08 <0.08 Posaconazole 0.24 1.3 0.47 Prophylactic treatment with Compound (I), inhibited inflammatory cell accumulation in BALF (Table 10), in a similar fashion to posaconazole. In addition, prophylactic treatment with Compound (I) showed superior inhibitory effects to posaconazole versus lL-17, lFNy and MDA trations in BALF, and the comparative |D5o values for Compound (I) and for posaconazole in ndent experiments are displayed in Table 11.

Table 10: The Effects of Prophylactic and eutic Treatment with Compound (I) on macrophage and neutrophil accumulation into the BALF of Aspergi/Ius fumigatus infected, immunocompromised, neutropenic mice.

Cell numbers in BAL L Drug Conc Treatment (% inhibition) (mglmL) Macrophage Neutrophil Vehicle + Spores 0.65 1r 0.14 0.49 1r 0.09 0.08 0.40 1r 0.15 (38) 0.37 1r 0.04 (24) Compound (I) Prophylactic 0.4 0.32 1r 0.07 (51) 0.26 1r 0.12 (47) Treatment 2 0.26 1r 0.05 (60) 0.22 1r 0.04 (55) 0.4 0.43 1r 0.05 (34) 0.38 1r 0.04 (22) nd (I) Therapeutic 2 0.40 1r 0.11 (38) 0.34 1r 0.05 (31) Treatment 0.32 1r 0.07 (51) 0.27 1r 0.08 (45) Table footnotes: The data for cell number are shown as the mean i standard error of the mean (SEM), N = 5-6.

Table 11: |D5o values for Prophylactic Treatment with Posaconazole and Compound (I) on IL- 17, lFNy and MDA levels in BALF in Aspergi/Ius fumigatus infected, immuno-compromised, neutropenic mice.

Drug substance IDso Values for biomarkers indicated (mglmL) (Prophylactic Regimen) lL-17 lFNy MDA nd (I) 0.074 <0.08 0.11 Posaconazole 0.61 0.22 0.69 rmore, data showing the effects of Compound (I) on lFNv, lL-17 and MDA levels in the BALF, when administered either prophylactically or therapeutically, are shown in Table 12 and the effects on serum, lL-6 and TNFd are shown in Table 13.

Table 12: The Effects of Prophylactic and Therapeutic Treatment with Compound (I) on lFNv, lL-17 and MDA levels in the BALF of Aspergi/Ius fumigatus infected, compromised, neutropenic mice.

Biomarker Concentrations in BALF (% Inhibition) Treatment Drug Conc Regime" e lFNy lL-17 MDA (pglmL) (pglmL) (uglmL) Vehicle + Spores 9.2 1r 1.0 19.8 1r 3.6 1.8 1r 0.2 0.08 3.7 i 1.7 (60) 9.8 i 5.3 (51) 0.96 i 0.32 (47) C°mp°”"d.(') 0.4 3.0 i 0.8 (67) 6.7: 4.9 (66) 0.57 i 0.22 (68) prophylactic 2 2.5 i 0.3 (73) 3.2 i 0.8 (84) 0.34 i 0.05 (81) 0.4 4.3 i 2.2 (53) 8.5 i 2.9 (57) 0.45 i 0.10 (75) C°mp°”"d. (D 2 3.3 i 0.8 (64) 4.0 i 0.8 (80) 0.37 i 0.10 (79) therapeutic 2.1 i 0.3 (77) 2.9 i 0.7 (85) 0.25 i 0.05 (86) Table tes: The data for biomarker concentrations are shown as the mean i standard error of the mean (SEM), N = 5-6.

Table 13: The Effects of Prophylactic and Therapeutic Treatment with Compound (I) on lL-6 and TNFd levels in the serum of i/Ius fumigatus infected, immunocompromised, neutropenic mice Conc of Biomarkers ) Treatment Drug Conc (% Inhibition) Regimen (mglmL) lL-6 TNF01 Vehicle + Spores 284 1r 112 25.6 1r 8.0 0.08 159 1r 73.3 (44) 11.8 1r 5.9 (54) Compound (I) Prophylactic 0.4 86.3 1r 46.9 (70) 7.3 1r 3.5 (71) Treatment 2 44.5 1r 12.2 (84) 4.7 1r 0.4 (82) 0.4 51.7 1r 16.8 (82) 6.2 1r 0.5 (76) Compound (I) Therapeutic 2 44.2 1r 11.4 (84) 5.5 1r 0.7 (79) Treatment 35.9 1r 10.4 (87) 4.9 1r 0.6 (81) Table footnotes: The data for biomarker concentrations are shown as the mean i standard error of the mean (SEM), N = 5-6.

Therapeutic treatment with Compound (I) was also found to maintain potent tion of lung fungal load, serum galactomannan levels and on BALF cytokine concentrations in Aspergi/lus fumigatus infected, immunocompromised, neutropenic mice. (Tables 7, 8 9 and 10 and Figs. 1, 2 and 3).

The effects of extended prophylactic dosing with Compound (I) on biomarkers in Aspergi/lus fumigatus infected, immuno-compromised, neutropenic mice were also ted. Extended prophylaxis with Compound (I) was found to inhibit fungal load in the lung, as well as the GM concentrations in both BALF and serum, at 25 fold lower doses than those used in a us biomarker study (Table 14). Furthermore, the data suggest an accumulation of anti-fungal effects in the lung on repeat dosing since seven days of prophylaxis produced r anti- fungal effects than did prophylactic treatment for a single added day. The compounds persistence of action in the lung is suggested by the finding that treatment on days -7 to day 0 generated superior anti-fungal effects on day 3 than those resulting from treatment on days -1 and 0, only. Nevertheless this abbreviated dosing protocol was still protective Table 14 Effects of extended prophylactic dosing of Compound (I) on fungal load (CFU) in lung and GM concentrations in BALF and serum in Aspergi/lus fumigatus infected, immunocompromised , neutropenic mice. ent Dose of Values and % Inhibition of response3 Reg'me"' 1 C°m|°°und “I CFU GM in BALF GM in Serum (Days d°sed) (”9’le (Img of lung) (COI) (COI) Vehicle plus Sporesz None 3475107 51:09 43:10 -7 to +3 3.2 8.3:2.0 (78) 2.6iO.36 (49) 43 (58) -1 to +3 3.2 95:33 (73) 2.8:071 (45) 2.2:069 (49) -7 to +3 18 50:23 (88) 1.75039 (87) 1.45020 (87) -1 to +3 18 6.1:2.8 (82) 1 (57) 41 (83) -7 to o 18 6.7:17 (81) 23:052 (55) 1.75059 (80) -1, o 18 13.1:26 (82) 4.54.050 (12) 4.0:0.88 (7) Table footnotes: 1. The N value was six for all drug treated groups; 2. The N value was five for the vehicle treated group; 3. The data for fungal load and GM levels are shown as the mean i standard error ofthe mean and the percentage inhibition, with respect to vehicle.

The influence on survival of combining the treatments of nd (I), dosed lly, with oral Posaconazole, was ted in severely immuno-compromised, neutropenic mice after inoculation with Aspergi/lus tus. Monotherapy with Compound (I) (0.4 mg/mL, given intranasally) or with Posaconazole (1.0 mg/kg, dosed orally) showed only a very limited therapeutic benefit. In contrast, the combination of Compound (I) and Posaconazole demonstrated a marked se on survival time following infection (Table 15).

Table 15 Effects of Compound (I) and Posaconazole as erapy or in combination on survival in severely immune-compromised, neutropenic mice ed with Aspergillus fumigatus.

No. of Median Log-rank test Treatment Dose (Route) . . . survuvors al Regimen for_survu_val on day 7 (%) (days) fect|on) Vehicle none 0/6 (0) 5 - Compound (I) 0.4 mg/mL (in) 0/6 (0) 6 p<0.05 Posaconazole 1 mg/kg, (po) 0/6 (0) 6.5 Not significant Compound (I) 0.4mg/mL (in) plus 5/6 (83) Undefined p<0.001 Posaconazole 1mg/kg (I00) Table footnotes: N = 8 per group.

In Vivo Pharmacokinetics It is a commonly used procedure for pulmonary, therapeutic agents to be dosed into the lungs of animals, for example mice, and plasma collected at various time points after dosing in order to characterise the ing systemic exposure to the administered compound. The compound of the invention may be tested in such in vivo systems.

Summary of the Biological Profile of Compound (I) Compound (I) has been found to be a potent inhibitor of illus fumigatus planktonic growth and bronchial epithelial cell ion. Compound (I) also ted the growth of posaconazole-resistant and nazole-resistant Aspergillus fumigatus isolates, trating greater potency than posaconazole, voriconazole and intraconazole against these strains. Compound (I) was also found to be a potent inhibitor of the growth of Rhizopus oryzae, Cryptococcus neoformans, Chaetomimum globosum, Penicil/ium chrysogenum and Trichophyton rubrum as well as some Candida Spp. In an in vitro model of alveoli, Compound (I) showed impressive activity against Aspergillus invasion, both as monotherapy and when dosed in combination with posaconazole. In vivo, in Aspergillus fumigatus infected, immunocompromised, neutropenic mice, nd (I), demonstrated potent inhibition of Aspergillus fumigatus infection, as well as the associated lung immune response whether dosed prophylactically or as a treatment. Compound (I) was also highly efficacious in reducing infection-dependent body weight loss. These inhibitory effects were superior to those of posaconazole. It is significant that the beneficial ungal effects of Compound (I) are observed in both a prophylactic and a therapeutic setting.

References Agbetile, J., Fairs, A., Desai, D., Hargadon, B., Bourne, M., Mutalithas, K., Edwards, R., , J.P., Monteiro, W.R., Kulkarni, N.S., Green, RH, Pavord, |.D., Bradding, P., Brightling, C.E., Wardlaw, A.J. and Pashley, C.H. Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1. Clin. Exp. Allergy, 2012, 42, 782-91.

Bafadhel M., McKenna 8., Aqbetile J., Fairs A., Desai D., Mistry V., Morley J.P., Pancholi M., Pavord |.D., Wardlaw A.J., Pashley CH. and Brightling C.E. Aspergillus fumigatus during stable state and exacerbations of COPD. Eur. Respir. J., 2014, 43, 64-71.

Bowyer P. and Denning D.W. Environmental fungicides and triazole resistance in Aspergillus.

Pest Management Science, 2014, 70, 173-178.

Chishimba L., Niven R.M., Fom M., Cooley J. and Denning D.W. nazole and Posaconazole lmprove Asthma Severity in Allergic opulmonary Aspergillosis and Severe Asthma with Fungal Sensitization. Pharmacotherapy, 2012, 49, 423-433.

Chotirmall S.H., O'Donoghue E., Bennett K., Gunaratnam C., O'Neill SJ. and McElvaney N.G.

Sputum Candida albicans es FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest, 2010, 138, 1186-95.

CLSI M27-A2: Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 2nd ed, NCCLS document M27-A2, Clinical and Laboratory Standards Institute, Wayne, PA, 2002.

CLSI M38-A2: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard, 2nd ed, CLSI document , al and Laboratory Standards Institute, Wayne, PA, 2008.

Denning D.W., Pleuvry A. and Cole D.C. Global burden of c pulmonary aspergillosis as a sequel to pulmonary ulosis. Bulletin of the World Health zation, 2011a, 89, 864- 872.

Denning D.W., Park 8., Lass-Flori C., Fraczek M.G., Kirwan M., Gore R., Smith J., Bueid A., 40 Moore C.B., Bowyer P. and Perlin D.S. High frequency triazole resistance found in nonculturable aspergillus tus from lungs of patients with chronic fungal disease. Clin.

Infect. Dis., 2011b, 52, 1123-1129.

Dimopoulos G., Frantzeskaki F., ou G. and Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann. NYAcad. Sci., 2012, 1272, 31-39.

Geist M.J.P., Egerer G., Burhenne J., Riedel K-D. and Mikus G. Induction of voriconazole metabolism by in in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications.

Antimicrob. Agents Chemother., 2007, 51, 3455-3456.

Hope W.W., Kruhlak M.J., Lyman C.A., Petraitiene R., Petraitis V., Francesconi A., Kasai M., Mickiene D., Sein T., Peter J., Kelaher A.M., Hughes J.E., Cotton M.P., Cotten C.J., Bacher J., Tripathi S., Bermudez L., Maugel T.K., Zerfas P.M., Wingard J.R., Drusano G.L. and Walsh T.J. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect.

Dis., 2007, 195(3), 455-466.

Jeong S., Nguyen PD. and Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.

Antimcrob. Agents Chemother., 2009, 53, 1.

Kaur S. and Singh S. m ion by Aspergillus fumigatus. Med. , 2014, 52, 2-9.

Kimura G., Ueda K., Eto S., Watanabe Y., Masuko T., Kusama T., Barnes P.J., lto K. and Kizawa Y. ike receptor 3 stimulation causes corticosteroid-refractory ainNay neutrophilia and hyper-responsiveness in mice. Chest. 2013, 144, 99-105.

Let A and Thompson GR. Update on the optimal use of voriconazole for ve fungal infections. Infect. Drug Resist, 2011, 4, 43-53.

Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., Davies S.F., Dismukes W.E., Hage C.A., Marr K.A., Mody C.H., t JR. and Stevens D.A. An Official American Thoracic Society Statement: ent of Fungal Infections in Adult Pulmonary and Critical Care Patients. Am. J. Respir. Crit. Care Med, 2011, 183, 96-128.

Levin M-D., den Hollander J.G., van der Holt 8., Rijnders B.J., van Vliet M., Sonneveld P. and van Schaik R.H. Hepatotoxicity of oral and intravenous nazole in relation to cytochrome P450 rphisms. J. Antimicrob. Chemother., 2007, 60, 1104-1107.

Lin S-J, Scranz J and Teutsch S.M. Aspergillus case-fatality rate: systematic review of the literature. Clin. Infect. Dis., 2001, 32, 358-366.

Monteiro M.C., de la Cruz M, Cantizani J., Moreno C., Tormo J.R., Mellado E, De Lucas J.R., Asensio F., Valiante V., Brakhage A.A., Latgé JP, Genilloud O., Vicente F. A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus tus using resazurin. J. Biomol. Screen. 2012, 17, 542-549.

Pasqualotto A.C., Powell 6., Niven R. and Denning D.W. The effects of antifungal therapy on severe asthma with fungal sensitization and ic opulmonary illosis.

Respiro/ogy, 2009, 14, 1121-127.

Pierce C.G., Uppuluri P., Tristan A.R., Wormley F.L. Jr., Mowat E., Ramage G., Lopez-Ribot J.L. A simple and reproducible l plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc., 2008, 3, 1494-500.

Rankin, N. Disseminated aspergillosis and moniliasis associated with granulocytosis and antibiotic therapy. Br. Med. J., 1953, 183, 918-9.

Rodriguez-Tudela J.L., up M.C., Arikan S., Barchiesi F., Bille J., Chyssanthou E., Cuenca-Estrella M., Dannaoui E., Denning D.W., Donnelly J.P., Fegeler W., Lass-Flori C., Moore C., Richardson M., Gaustad P., Schmalreck A., Velegraki A. and VenNeij P.

Subcommittee of Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility testing (EUCAST). EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. E.DEF 9.1 2008, 1-13.

Salmeron G., Porcher R., Bergeron A., Robin M., Peffault de Latour R., Ferry C., Rocha V., Petropoulou A., Xhaard A., Lacroix C., Sulahian A., Socie G., and Ribaud P. Persistent poor long-term prognosis of alogeneic hematopoietic stem cell transplant recipients surviving invasive llosis. Haematolo/ogica, 2012, 97, 1357-1363.

Thompson GR. and Patterson T.F. Pulmonary aspergillosis. Seminars in Respiratory and Critical Care ne, 2008, 29, 103-110.

Wexler D., Courtney R., ds W., ld C., Lim J. and Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label two-way crossover study. Eur. J. Pharm. Sci, 2004, 21, 65-653.

Throughout the specification and the claims which follow, unless the t requires otherwise, the word ‘comprise’, and ions such as ‘comprises’ and ‘comprising’, will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps. 21339411.1:DCC - 26/03/2021

Claims (8)

1. Claims 1. A compound, namely Compound (I), which is: 4-(4-(4-(((3R,5R)((1H-1,2,4-triazolyl)methyl)(2,4- difluorophenyl)tetrahydrofuranyl)methoxy)methylphenyl)piperazinyl)-N-(4- fluorophenyl)benzamide; 10 or a ceutically acceptable salt thereof.
2. 2. Use of a compound according to claim 1 in the manufacture of a medicament for the treatment of mycoses or for the prevention or ent of disease associated with mycoses. 15
3. 3. The use according to claim 2 wherein the s is caused by Aspergillus spp.
4. 4. The use according to claim 3 wherein the Aspergillus sp. is Aspergillus fumigatus or Aspergillus pullulans especially Aspergillus fumigatus. 20
5. 5. The use ing to claim 3 wherein the illus sp. is an azole resistant Aspergillus fumigatus.
6. 6. The use according to claim 2 wherein the mycosis is caused by Candida spp., us spp., Cryptococcus spp., Penicillium spp., or Trichophyton spp.
7. 7. A pharmaceutical composition comprising a compound according to claim 1 in combination with one or more pharmaceutically acceptable diluents or carriers.
8. 8. A pharmaceutical composition according to claim 7 which comprises a second or 30 further active ingredient. [Link] https://en.m.wikipedia.org/wiki/Candicidin [Link] https://en.m.wikipedia.org/wiki/Filipin [Link] https://en.m.wikipedia.org/wiki/Hamycin [Link] //en.m.wikipedia.org/wiki/Natamycin [Link] https://en.m.wikipedia.org/wiki/Nystatin [Link] https://en.m.wikipedia.org/w/index.php?title=Rimocidin&action=edit&redlink=1 [Link] https://en.m.wikipedia.org/wiki/Bifonazole [Link] https://en.m.wikipedia.org/wiki/Butoconazole [Link] https://en.m.wikipedia.org/wiki/Clotrimazole [Link] https://en.m.wikipedia.org/wiki/Econazole [Link] https://en.m.wikipedia.org/wiki/Fenticonazole [Link] //en.m.wikipedia.org/wiki/Isoconazole [Link] https://en.m.wikipedia.org/wiki/Ketoconazole [Link] https://en.m.wikipedia.org/wiki/Luliconazole [Link] https://en.m.wikipedia.org/wiki/Miconazole [Link] //en.m.wikipedia.org/wiki/Omoconazole [Link] https://en.m.wikipedia.org/wiki/Oxiconazole [Link] https://en.m.wikipedia.org/wiki/Sertaconazole [Link] https://en.m.wikipedia.org/wiki/Sulconazole [Link] https://en.m.wikipedia.org/wiki/Tioconazole [Link] https://en.m.wikipedia.org/wiki/Efinaconazole [Link] https://en.m.wikipedia.org/wiki/Epoxiconazole [Link] https://en.m.wikipedia.org/wiki/Fluconazole [Link] https://en.m.wikipedia.org/wiki/Isavuconazole [Link] https://en.m.wikipedia.org/wiki/Itraconazole [Link] https://en.m.wikipedia.org/wiki/Propiconazole [Link] https://en.m.wikipedia.org/wiki/Ravuconazole [Link] https://en.m.wikipedia.org/wiki/Terconazole [Link] https://en.m.wikipedia.org/wiki/Abafungin [Link] https://en.m.wikipedia.org/wiki/Amorolfin [Link] https://en.m.wikipedia.org/wiki/Butenafine [Link] https://en.m.wikipedia.org/wiki/Naftifine [Link] https://en.m.wikipedia.org/wiki/Terbinafine [Link] https://en.m.wikipedia.org/wiki/Anidulafungin [Link] https://en.m.wikipedia.org/wiki/Micafungin [Link] https://en.m.wikipedia.org/wiki/Benzoic_acid [Link] https://en.m.wikipedia.org/wiki/Flucytosine [Link] https://en.m.wikipedia.org/wiki/Griseofulvin [Link] https://en.m.wikipedia.org/wiki/Tolnaftate [Link] https://en.m.wikipedia.org/wiki/Undecylenic_acid 11.1:DCC -